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Foreword – Minister of State
I am happy to welcome this new review of harm reduction approaches from the NACD. This report
arises out of Action 100 in the National Drugs Strategy which called for research into the effectiveness
of new mechanisms to minimise the sharing of equipment and to establish the potential application 
of new options within particular cohorts of the drug using population. It is part of the Government's
commitment to building knowledge to inform policy development and appropriate strategies. 
As the report points out, harm reduction approaches can make a significant contribution to the health
of drug misusers and they form an important part of Irish drugs policy. However, in common with all
approaches to the drug problem, harm reduction policies need to evidence-based. It is for this reason
that this review of the international literature on harm reduction and the Irish experience of harm
reduction approaches is so welcome. 
The research and analysis provided by the NACD is particularly helpful to the policy development
process and also to developing best practice in service delivery. This report examines how we deliver
harm reduction in Ireland and where we can enhance and improve our service delivery as part of the
overall National Drugs Strategy. I have noted the conclusions of the review and have no doubt that
they will inform the ongoing review of the Strategy. 
Finally, I would like to record my appreciation of the on-going work of all of the members of the
National Advisory Committee on Drugs, in particular, its Chairperson - Dr. Des Corrigan, its Director -
Ms. Mairéad Lyons and its Research Officer - Ms. Aileen O’Gorman. 
Noel Ahern T.D.
Minister of State with responsibility for the National Drug Strategy
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Foreword – Chairperson NACD
It is clear that our primary aim is to reduce the demand for drugs and to prevent people from taking
drugs in the first place. However, we are faced with the reality that many people take drugs and thus
they face risks to their health. More importantly, sharing equipment used to administer drugs carries
with it a high degree of risk of injury and contracting blood borne infections. As patterns of drug use
change, new ways of administering drugs and new drug preferences emerge, we need to be ever 
more vigilant in how we communicate with drug users about minimising harm to their health.
Commissioned by the NACD in response to Action 100 of the National Drug Strategy, this Review was
prepared by a team from Dublin City University (DCU) and the NACD is grateful to them for their work.
It is clear from this Review that Irish harm reduction services need to be more flexible, be available 
in all health boards and in areas of greatest need. Alternative approaches should be considered to
support the expansion of harm reduction services such as Community Pharmacy Needle Exchange. 
Moreover, this Review shows that harm reduction programmes do not increase experimentation with
drugs and that they can limit the spread of blood borne infections. Harm reduction services should
have the flexibility to cater for the provision and/or exchange of a range of drug use paraphernalia 
so as to reduce the risk of contracting drug related infectious diseases and other harm. We know 
that Hepatitis C Virus, in particular, is a very resilient organism and this has implications for sharing 
any piece of drug taking equipment. As part of that greater flexibility, there is a need for enhanced
training for service providers. Service provision to drug users in prisons should mirror that available 
in the community.
We know that we must strive to continuously improve our services to drug users and take every
opportunity when in contact with drug users to give them accurate information about risks of harm 
with a view to firstly helping them modify their risky behaviour and ultimately encouraging them 
into services. 
In presenting this Review to all those involved in responding to the drugs phenomena, the NACD
hopes it will help stimulate and inform discussions among policy makers and service planners across 
all sectors.
Dr Des Corrigan
Chairperson
NACD
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Abbreviations
ECAHB East Coast Area Health Board
ERHA Eastern Regional Health Authority
HBV Hepatitis B Virus
HCV Hepatitis C Virus
HIV Human Immunodeficiency Virus
IDU Intravenous Drug Use/User
IDUs Intravenous Drug Users
INCB International Narcotics Control Board
NACD National Advisory Committee on Drugs
NAHB Northern Area Health Board
NDS National Drug Strategy 2001-2008
NEPs Needle Exchange Programmes*
SEPs Syringe Exchange Programmes*
STDs Sexually Transmitted Diseases
SWAHB South Western Area Health Board
WHO World Health Organisation
* NEPs and SEPs are used interchangeably in the literature and are understood by the authors to
mean a service that offers a range of drug-taking equipment and health care advice to IDUs
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Executive Summary
In 2002, the National Advisory Committee on Drugs (NACD) commissioned a review of the
International Literature on Harm Reduction and of services available in Ireland, as part of its response
to Action 100 in the National Drug Strategy 2001-2008. Following open tender, Dublin City University
was awarded the contract. The research team reviewed the international literature and carried out
primary research in health services in Ireland on approaches to harm reduction. This report considers
the evidence and the summary here presents the key findings.
Harm reduction is a concept aiming to prevent or reduce negative health consequences associated
with certain behaviours. In relation to drug misuse, harm reduction components of comprehensive
interventions aim to prevent transmission of HIV and other infections that occur through sharing of
drugs and non-sterile drug-taking paraphernalia. 
One of the trends evident in problem-drug-use research is the increasing emphasis on measures 
to limit sharing of equipment used in drug administration. The rationale for this approach is that 
it reduces the potential for harm associated with drug use, as part of a wider move toward harm
reduction. Illicit drug use is a behaviour that exposes the drug user to a variety of risks. There is 
a relatively high rate of opiate drug use in Ireland generally estimated at 5.6 per thousand of the
population (Kelly, Carvalho, & Teljeur, 2003). In a European context the highest estimates are reported
for Italy, Luxembourg, Portugal and the United Kingdom. Estimates are lowest in Austria, Germany 
and the Netherlands, placing Ireland in the middle band of the estimates for problem drug users in the
population. There is extensive scope for health and social gain among problem drug users, particularly
among groups that are challenging to engage, such as young drug users and those who are homeless
or in prison. The utility of harm reduction techniques in reducing shared use of drug-taking
paraphernalia therefore merits systematic investigation. 
The aim of harm reduction efforts is to minimise the risks stemming from shared use of drug-use
paraphernalia such as syringes, pipes, spoons and filters. A number of strategies are used, including
increased flexibility and responsiveness of drug services, needle/syringe exchange programmes 
(NEPs/SEPs), exchange of other drug-use paraphernalia, tailoring initiatives to the characteristics 
of target groups, safe injecting facilities, and education and support of drug users who share drug-
administration equipment. These methods are designed to lower the negative impact on health and
functioning that is associated with drugs misuse, particularly as a consequence of infection with blood-
borne diseases. 
Harm reduction principles can be used successfully to address the adverse impact on health outcomes
and Quality of Life associated with sharing drug-use equipment. The preliminary primary research into
practices among Irish drug services indicates that harm reduction methods are being used in Ireland.
However, the general picture is that there is significant scope to expand drug services’ role in
delivering flexible and responsive initiatives to target shared use of drug-taking paraphernalia. For
instance, the restricted opening hours and limited number of needle exchange services may contribute
to continued sharing of equipment. Changes in patterns of drug use may require concomitant changes 
in the delivery of health services.
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There are a number of public concerns regarding harm reduction measures. These are related to
perceived risks to public health and safety arising from criminal activity associated with drug use, and 
to the unsafe disposal of drug-taking paraphernalia. These concerns have impacted on the development
and uptake of harm reduction programmes in Ireland and abroad. Anxieties related to community
presence of harm reduction programmes are difficult to allay. However, there is evidence that NEPs 
are effective in preventing Human Immunodeficiency Virus (HIV) infection without being associated 
with a rise in injecting drug use. 
All of the routes for administering illicit drugs lead to increased risk of HIV, Hepatitis B (HBV) and
Hepatitis C (HCV) transmission, when equipment is shared. While NEPs have been successful in reducing
the risk of sharing needles, they tend not to impact on the sharing of other drug-use paraphernalia.
Harm reduction programmes generally aim to minimise the sharing of all drug-taking paraphernalia 
as, for instance, non-injecting paraphernalia is also associated with increased risk of contracting diseases
such as HIV and HCV. Harm reduction programmes appear to be less successful in containing HCV than
in slowing the spread of HIV. There are examples of comprehensive NEPs significantly impacting on the
rate of HCV infection, by placing greater emphasis on the factors involved in HCV transmission.
Spoons are the most frequently shared piece of injecting paraphernalia yet needle exchange
programmes have been the focus of considerable research. Contaminated spoons, water or solvent 
and filters can all spread bacterial and viral infections. Irish services tend to focus on needle exchange in
their harm reduction efforts with Intravenous Drug Users (IDUs). For instance, services do not exchange
pipes for drug users who practise this method of administration. Strategies such as encouraging IDUs 
to utilise methods of administration other than injecting can assist in lowering risk of infection.
In addition to offering equipment exchange, a number of harm reduction programmes have included
education of drug users with regard to risky drug use practices. Behavioural habits can be addressed 
in addition to education and support on specific techniques. For instance, drug users sometimes attach 
a lower risk to sharing equipment with partners and close contacts, and there seem to be implicit norms
regarding borrowing and lending of administration equipment. Further work is required to devise best
practice guidelines relevant to education and support, with consideration of staff development 
and education.
Specific risk factors for the sharing of drug-use equipment include youth, a shorter injecting history,
confinement to prison, homelessness and being involved in a sexual relationship with another IDU. Work
with young users requires particular engagement strategies, as younger drug injectors are less likely to
heed the harm reduction message of safe injecting practices. Relevant harm reduction messages aimed
at sexual partners of IDUs can heighten awareness of the risks associated with having unprotected sex
with drug injectors who are sharing equipment.
The prison environment presents particular challenges for the implementation of harm reduction
strategies, but a substantial body of evidence indicates the utility of expanding harm reduction efforts 
in prisons. Needle sharing in prison is the most important risk factor for the transmission of HIV, HCV 
and HBV among IDUs. Studies carried out in Ireland indicate increased prevalence rates of blood-borne
infections among drug injectors who have been in prison, than among injectors who have not been in
prison. International research indicates that the introduction of relevant harm reduction programmes in
prison, such as equipment exchange, can help reduce HIV and HCV transmission rates, without a
subsequent increase in the rate of illicit drug consumption.
Supervised drug consumption rooms have been introduced in several countries. The aim of this harm
reduction technique is to lower the incidence of blood-borne disease transmission and to support
health needs generally, through increased access to primary health care and social services. These
facilities can promote increased contact with services for the most marginalised IDUs, however, the
evidence of their effectiveness is weak. The prescription of heroin has also been subject to trials at 
a number of international settings and outcome evaluations have not been able to show direct benefit.
Currently, supervised drug consumption rooms and heroin provision are not part of the range of harm
reduction measures available in Ireland. Legal restrictions in relation to the operation of supervised
drug consumption rooms and heroin provision exist. The introduction of supervised drug consumption
rooms would require changes in national legislation and careful consideration of the impact of such
strategies in reference to international treaties. 
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Chapter 1
Introduction and Methodology 
Background
There is a relatively high rate of opiate drug use in Ireland, generally estimated at 5.6 per thousand 
of the population (Kelly, Carvalho, & Teljeur, 2003). In a European context the highest estimates are
reported for Italy, Luxembourg, Portugal and the United Kingdom, with between six and nine problem
drug users per 1000 inhabitants of the 15-64 year old population. Estimates are lowest in Austria,
Germany and the Netherlands with about three problem drug users per 1000 inhabitants aged 15-64
(European Monitoring Centre for Drugs and Drug Addiction 2002). These figures place Ireland in the
middle band of the estimates for problem drug users in the population. 
In September 2002, the NACD commissioned a review of national and international harm reduction
research as part of its responsibility under Action 100 of the National Drugs Strategy “to conduct
research into the effectiveness of new mechanisms to minimise the sharing of equipment e.g. non-re-
usable syringes, mobile syringe-exchange facilities etc. to establish the potential application of new
options within particular cohorts of the drug-using population i.e. amongst younger drug users, within
prisons etc.” (National Drug Strategy, 2001). The tender brief outlined a number of important areas in
harm reduction that required consideration:
■ An overview of drug-taking techniques and the paraphernalia used in the administration of 
illicit drugs
■ A review of international approaches to harm reduction
■ A review of national approaches to harm reduction
■ A review of the uptake, effectiveness and limitations of harm reduction approaches nationally
■ An international review of alternative and innovative initiatives which may have potential
applications to Ireland
■ A review of the issues involved in operating such schemes. 
A deficit of published literature was anticipated in some of the core elements of the review, including
the operation of harm reduction programmes nationally. These issues were addressed through an
exploratory empirical study to obtain information directly from service providers. 
Report Outline
This report presents a review of the research literature and the findings of preliminary research into the
harm reduction practices of Irish drug services. The report is presented as eleven separate chapters
outlined below. Chapter one, as well as describing the methodology employed, presents information
on the NACD brief for this report. This is followed by a global review of harm reduction in chapters 
two to six. Material that specifically relates to Ireland has, where possible, been grouped in the latter
chapters of the report. However the authors have been mindful to provide appropriate links between
national and international research. 
Chapter two outlines definitions of harm reduction in the context of approaches aimed at minimising
the sharing of equipment used to administer drugs. This is followed by an exploration of the methods,
tools and routes used in the administration of drugs in chapter 3. Chapter four is concerned with 
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NEPs as a harm reduction strategy. The range of sites from which NEPs operate, along with their
effectiveness in the reduction of the transmission of blood-borne diseases is considered. In chapter
five, drug consumption rooms and heroin provision are examined in reference to international
experiences and trials of such services. Chapter six examines the effectiveness of harm reduction 
as a strategy in reducing the transmission of HIV, HCV and HBV. 
Commencing with chapter 7, the report concentrates on harm reduction strategies in relation to 
Irish developments, and a review of national developments of harm reduction programmes. This is
followed by a presentation of information from primary sources about the day-to-day work conducted
in Irish harm reduction services. Chapter nine presents information on harm reduction in relation to
marginalised groups such as women, travellers, prisoners and the homeless. Both the national and
international research in relation to prisons is presented. The relevant Irish law and international
treaties that govern the supply, preparation and consumption of controlled drugs are discussed in
chapter ten which is followed, in chapter eleven, by a drawing together of the report’s conclusions. 
Search Strategy
The literature review for the study was based on a structured search of relevant research databases 
and other sources, the compilation of primary conceptual, methodological and empirical research, 
and an analysis of the research and integration of the findings. A series of search terms was used to 
find relevant research: harm reduction; harm reduction and service provision; harm reduction and risk
factors; harm reduction/prisons; needle/syringe exchange; heroin; heroin provision; cocaine; drug
use/misuse; drug addiction; injecting drug use; drug-taking paraphernalia; harm minimisation; and
prevention. Researchers and workers in the area of addiction were contacted for information. The
NACD research advisory group provided expert input to the design of the project. Search engines
included CINAHL, PSYCLIT, Science Direct, the Cochrane Library, PubMed and Medline to ensure
targeting of information from medicine, psychology, nursing and other relevant disciplines. The
websites of relevant organisations were visited for information, including the NACD, the Government
of Ireland, the World Health Organisation, the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), the INCB and the UN. 
Selection Criteria
Reviewed material was restricted to the English language. Research published up until July 2003 was
included in the literature review. 
Data Collection and Analysis
Some of the search terms were broad; therefore each abstract in the strictly defined terms of the report,
harm reduction approaches aimed at minimising sharing of equipment used to administer drugs, was
reviewed. A general review of more broad terms was conducted to ensure the comprehensiveness of
the research. Where an abstract was found to be relevant, the full article was sought and reviewed by a
minimum of two of the authors of this report. In the case of annual reports or Government publications,
the complete report was sought and reviewed for consideration of inclusion in this report. This resulted
in the inclusion of almost 150 published articles and reports in the review. 
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Chapter 2 
Harm Reduction
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This chapter provides definitions of harm reduction in the context of approaches aimed at minimising
sharing of equipment used to administer drugs. The problems in defining harm reduction are 
examined. The advantages of, and concerns about, harm reduction as a strategy to address the 
health risks associated with drug use are addressed. The international development of harm reduction
programmes is considered. 
Defining Harm Reduction
The World Health Organisation (WHO 2003) defines harm reduction as a concept aiming to prevent 
or reduce negative health consequences associated with certain behaviours. In relation to drug injecting,
the ‘harm reduction’ components of comprehensive interventions aim to prevent transmission of 
HIV and other infections that occur through sharing of non-sterile injecting equipment and drug
preparations (WHO 2003). Harm reduction focuses on minimising the personal and social harm
associated with drug use and the spread of blood-borne diseases such as HIV, HCV and HBV (Hilton,
Thompson et al., 2001). This public health approach enables the client to choose the safest way of using
substances and provides necessary support and means in order to achieve the best possible outcome
(Rassool, 1998).
Up until the 1980s, drug services around the world were mainly directed towards ‘curing’ addictions. 
The idea of harm reduction emerged following anxiety about the failure of treatments for drug misuse 
in the 1960s and 1970s and the recognition that drug dependency in many cases is a long-term problem
for users and their families. Harm reduction has gained in popularity as a public health approach to drug
addiction treatment since the 1980s when concern about the transmission of HIV emerged (Robertson,
1998). Worldwide there may be as many as two to three million past and current injecting drug users
living with HIV/AIDS, and more than 110 countries now report HIV epidemics that are associated with
injecting drug use (WHO 2003). Interventions for injecting drug users that reduce HIV risk also have the
potential to engage drug users in treatment services that may ultimately lead to abstinence from drug
use. Such programmes can help drug users avoid other harmful consequences of drug use, including
HBV and HCV infections and deaths through overdose (WHO 2003). 
A harm reduction approach focuses on reducing the harm that substance users cause to themselves 
and to their families. Within this approach, there is acceptance of ongoing intervention rather than 
short-term or abstinence-orientated approaches. A harm reduction approach aims to reduce the
transmission of HIV, HCV, HBV and other infectious diseases and also helps to maximise service users’
and their families’ health. Hence harm reduction carries significant HIV prevention potential for both
injecting drug users and the general population (WHO 2003). 
Harm reduction programmes typically include a range of interventions, which, on a continuum,
commences with communication with drug users and the general public and moves to the prescription
of drug substitution treatment. Within the WHO (2003) definition any intervention that aims to prevent or
reduce negative health consequences associated with the behaviour of drug misuse could be perceived
as a harm reduction effort. However, it is important to distinguish between harm reduction, which aims
to prevent or reduce negative health consequences, and treatment, which can be defined as a method
of counteracting a disease (Collins English Dictionary 1996). The blurring of boundaries between what
constitutes harm reduction and what constitutes treatment is a cause of concern to those in the
addiction field. This is clear from the outline of typical harm reduction interventions set out below:
Harm Reduction Interventions
■ Information, education and communication on the health risks associated with drug use, which 
will assist drug misusers to avoid or modify their drug-taking behaviour; 
■ Health care in relation to infectious diseases associated with drug misuse which, as well as
providing screening and interventions for specific infections, offers support, information and
education; 
■ Needle exchange programmes, which aim to ensure that those who continue to use drugs have
access to clean injecting paraphernalia as well as to provide safe disposal of used equipment.
These programmes offer a range of equipment including needles, syringes, filters, cookers/spoons,
sterile water, swabs and citric acid. Disinfection programmes – the use of bleaching agents – have
been used in settings where needle exchange is not feasible (WHO 2003);
■ Drug substitution treatment involves the medically-supervised treatment of individuals with opioid
dependency based on the prescription of opioid agonists1 such as methadone. While the primary
goal of drug treatment is abstinence from illicit drug use, many patients are unable to achieve
complete abstinence, despite improvements in their health and well-being. However, there is 
clear evidence that methadone maintenance (substitution treatment) significantly reduces unsafe
injecting practices of those who are in treatment, and hence the risk of infection (WHO 2003). 
In the mid 1980s the aim of oral methadone prescribing in the Netherlands shifted from achieving
abstinence towards achieving stabilization and harm reduction (Van Den Brink et al., 1999). Similar
shifts have taken place elsewhere. However, it is important to distinguish between low-threshold
maintenance programmes, which have a harm reduction aim, and high-threshold programmes,
which are aimed at achieving abstinence (Office of National Drug Control Policy 2003). 
Other less typical harm reduction interventions include initiatives such as drug consumption rooms that
provide supervised facilities where drug misusers can consume drugs. These interventions are
examined later in the report. 
Problems in Defining Harm Reduction
Within the literature on harm reduction, there is continuing disagreement about the essential
components of harm reduction and how it is operationalised as an approach. There is no agreement
regarding the definition of harm reduction, and terms such as harm reduction, harm minimisation and
risk minimisation are used interchangeably. For the purpose of this report the WHO (2003) definition
will be utilised. Despite the ongoing debate about its components, harm reduction is a popular
approach and has become widely adopted. Harm reduction is mainly associated with injecting drug
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1 An opiate agonist has similar effects to the injected opiate on the body thus removing the need to inject.
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use (IDU) and the transmission of blood-borne infections. Harm reduction neither condones nor
condemns drug use, but respects drug use as a choice (Hilton et al., 2001).
Advantages of Harm Reduction
There is an accumulation of international evidence about the importance, feasibility and effectiveness
of different techniques for reducing drug-related harms. In the past, much of this evidence came from
projects designed to reduce the risks of HIV transmission. Stimson (1998) states that harm reduction 
is not only a philosophical and practical approach to a drug problem but that it can also positively
impact on the health status of IDUs. Overall, advocates for a harm reduction approach support their
arguments with a rationale based on safer injecting practices, reduced rates of contracting infectious
diseases and the curtailment of criminal activities.
Supporters of harm reduction argue that for drug users who can or will not discontinue drug use, the
best possible outcome may be for continued drug use under supervised and safer conditions. In
addition, Goldstein (2001) comments that access to reliable quality of drugs (instead of uncontrolled
illicit ones) may help to improve longevity and health. Some promoters of harm reduction aim to
undercut the black market and decrease criminal activities. HIV and AIDS have dramatically increased
the adverse health consequences of IDU so that drug use has come to be seen as a health problem, 
as well as a criminal justice issue.
Concerns and Criticisms Related to Harm Reduction
The concerns voiced about harm reduction vary according to the perspective of the commentator, but
are generally related to public health and safety, including the transmission of infectious diseases, the
legislation governing illicit drugs and the crime rate associated with drug use. 
Harm reduction requires an integrated approach including justice, education, drug treatment and 
other health programmes, in order to address the many problems associated with drug use (Des
Jarlais, 1995). One of the most common criticisms of the harm reduction approach is that it is the 
first step towards legalisation of currently illegal drugs. According to Des Jarlais (1995), there are 
critical differences between a public health harm reduction perspective and one based on libertarian
principles. Harm reduction remains controversial as it is perceived by some to give rise to accusations
of collusion with drug taking instead of seeking solutions (Robertson, 1998).
Another issue of concern facing harm reduction is that it is difficult ethically to subject it to scientific
scrutiny, for example, in the use of randomised controlled trials. Instead, case, longitudinal and cohort
studies are used. These highlight the interaction between national and local policies, the interventions
that are developed and how these interventions influence risk behaviours (Stimson, 1998). This is of
particular importance in addressing the health care needs of marginalised groups within the general
and drug-using population, including young people, prisoners and sex workers.
Differentiating between what constitutes harm reduction and what constitutes treatment is an issue
that requires consideration. Negrete (2001) questions the influence that an ideological movement
operating under the label of harm reduction appears to be exerting on treatment practices. This
argument focuses on how a health education agenda has developed from a ‘therapy’ curriculum. 
One explanation is a lack of distinction between the objectives of public health campaigns and the
purposes of individual treatment. Another explanation proposes a loss of concern among addiction
treatment planners and clinicians for the problem of drug dependence itself (Negrete 2001).
Methadone maintenance treatments have been shown to benefit drug users as well as providing 
public health and social benefits (Kreek 1992, Bell & Zador 2000, Negrete 2001). However, Negrete
(2001) is concerned that the harm reduction movement readily embraces low threshold methadone
maintenance and heroin prescribing. 
Zador (2001) argues that injecting of prescribed opiates per se does not reduce the risk of blood-borne
viral disease infection among injecting drug users – rather, reduced infection rates are predicated on
the use of clean needles, syringes and other equipment to inject street heroin, prescribed medications
or any other drug. It may be argued that injecting opiate treatment increases opportunities for
reinforcement of these harm reduction strategies. Most recently, heroin prescription has been on trial
in both Switzerland and the Netherlands. Heroin prescription is defined as a treatment. Studies on the
medical prescription of narcotics to drug-dependent persons are defined as scientific studies designed
to investigate the success of the proposed treatment as a step towards abstinence (Uchtenhagen et al.,
1999). Treatment programmes may, and do, contain elements of harm reduction as steps towards
abstinence. It is imperative that harm reduction programmes, which aim to prevent or reduce negative
health consequences, are distinctly identifiable in both their aim and execution so as not to be perceived
by those accessing or delivering them, or by the general public, as treatments for drug misuse. 
International Development of Harm Reduction Programmes
Harm reduction is a popular approach in public health and medical practice (Robertson, 1998). The
World Health Organisation (WHO) recognises that the spread of HIV is a greater danger to individual
and public health in comparison to drug misuse and requested that measures to reduce drug use do
not compromise efforts to curtail the spread of HIV (Riley, 1993). Many countries and organisations have
adopted harm reduction programmes (Hilton et al., 2001). 
The harm reduction perspective was first developed in industrialised countries, with important work
originating in the Netherlands, UK and Australia. Social and medical services for the management 
of IDUs vary internationally according to social, economic and medical perspectives and traditions.
From 1981, absolute abstinence was abandoned as the primary goal of all drug-misuse treatment
efforts in Amsterdam. Instead, the Dutch Drug Policy focused on harm reduction interventions. In the
same year this led to the introduction of low threshold methadone programmes. These were defined 
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as being harm reduction oriented with the aim of relieving withdrawal symptoms and craving while
improving patients’ quality of life. Needle exchange was introduced in Amsterdam in 1984 and is
further explored in Chapter 4.
Italian drug users could buy injecting equipment in the 1980s and NEPs were established in the UK
shortly afterwards. In Liverpool, the Merseyside project co-ordinated clinics, pharmacists and the police
force to establish a unique harm reduction model that prescribed drugs, provided needle exchanges
and supported drug users (Riley, 1993). 
In Australia in the 1980s, harm reduction programmes such as NEPs and safer sex education developed
in response to the risk of HIV (Wellbourne-Wood, 1999). Since 1995, harm reduction is the guiding
principle of Australia’s National Drug Policy. 
In 1987, the Canadian Government officially adopted harm reduction as the framework for Canada’s
National Drug Strategy defining harm in terms of sickness, death, social misery, crime, violence and
economic costs to all levels of Government (Riley, 1993). Canada’s first NEP opened in Vancouver in
1989 (Riley, 1993). 
Although a harm reduction approach was adopted with some enthusiasm in Europe and Australia,
acceptance has been slower in the United States. This may have been due to an abstinence-oriented
establishment and long history of tightly-controlled methadone provision (Robertson, 1998). 
Harm reduction is spreading to many developing countries with NEPs operating in Nepal, Thailand and
India. There is an Asian Harm Reduction Network which aims to support individuals and organisations
interested in implementing harm reduction efforts throughout Asia (Robertson, 1998).
Key Points
■ Harm Reduction focuses on minimising the health, personal and social harms associated with 
drug-use such as the spread of blood-borne diseases
■ Harm Reduction involves ongoing interventions for the IDUs
■ Where comprehensive Harm Reduction programmes exist, lower rates of HIV infection are reported
■ Clear distinction needs to be made between Harm Reduction programmes and drug misuse
treatments
■ Harm Reduction programmes, as a strategy to improve the health of IDUs, their families and the
general public, have grown internationally 
Chapter 3
Methods and Tools of Drug Administration 
In this chapter the reader is presented with a review of the varied routes and modes of drug
administration. This includes discussion on the paraphernalia required in the preparation of drugs for
administration. Sharing drug-taking paraphernalia is considered in relation to the factors that influence
this behaviour and its implications for the drug user. 
Drug Taking Techniques
The route and mode of drug administration vary for a number of reasons. These include the type 
of drug, the desire and concerns of the user, the availability of equipment and circumstances in the
particular environment of the user. This report is primarily concerned with the risks associated with
sharing equipment in drug users. The most-commonly-used drugs that require equipment for
administration by users are heroin and cocaine.
The opiate heroin can be taken by a variety of routes such as by smoking, skin-popping (which is
defined as injecting drugs under the skin and/or injecting drugs on any part of the body without 
hitting a vein), or it can be taken intravenously (Office of National Drug Control Policy 2003). 
Cocaine, a stimulant, is most commonly snorted or injected. Injecting cocaine requires frequent
administration. This implies that more paraphernalia is required by the drug misuser in order to 
avoid the harm of sharing. Inhalation of crack cocaine with the aid of a pipe is a recent and popular
administration route. All of the routes that require the use of equipment increase the risk of the
transmission of HIV, HBV and HCV when equipment is shared.
Sharing of injecting equipment can include the sharing of needles and syringes, the sharing of other
equipment used in preparation for injection such as spoons, cotton and water containers and the
sharing of drugs by transferring some of the contents from one syringe to another, commonly known 
as front- or back-loading (Speed, 1998). Sharing or ‘borrowing’ involves using equipment received from
another injector (Gossop, Griffiths, Powis et al., 1997). In donor sharing or ‘lending’, the injector passes
used injecting equipment to another person. Injectors often regard ‘sharing’ as referring only to
injecting with a syringe taken from another person but not referring to the act of passing a used
syringe to others (Koester, Booth & Zhang, 1990). Gossop et al. (1997) found that donor sharing of
syringes (lending used equipment) was more commonly reported than recipient sharing of syringes
(borrowing used equipment from others).
Preparing drugs frequently involves the use of a spoon or ‘cooker’ and a water container to flush
syringes before use and/or from which water is drawn to dissolve materials for injection. Sharing
accessories such as spoons, cotton, water, filters or front- and back-loading also known as ‘halving’ 
is often not perceived as sharing by drug users (Gossop et al., 1997). 
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Sharing Injecting Paraphernalia
In addition to syringe borrowing, there are other important unsafe injecting practices, which may
contribute to the spread of blood-borne viral infection such as HCV (Gossop et al., 1997). In his study
of shared use among 303 London heroin addicts, Gossop et al. (1997) investigated the extent to which
drug injectors passed syringes, spoons and water containers to be used by another person. They also
examined the sharing of equipment by the user after these had been previously used by another IDU
and the frequency with which such practices occurred with sexual partners, close friends and casual
acquaintances. 
In their study of IDUs, the majority of whom were male, a structured interview was administered and
saliva samples were taken from the majority of the sample. The predominant pattern of drug taking
was polydrug use. Multivariate analysis results indicated that respondents were more likely to report
sharing water containers or spoons than syringes. This effect was more evident amongst close friends
than amongst casual acquaintances and sexual partners. However, more than half of those who had a
sexual partner who was also an IDU reported only sharing spoons and water with them. Overall,
Gossop et al. (1997) concluded that nearly two thirds of the sample had engaged in some sort of
sharing practice with injecting equipment during the previous year. 
In a cross-sectional study of 97 regular attenders at five NEPs in the North West of England (89% who
used heroin, 5% who used cocaine), Speed (1998) reported that there is extensive sharing of injecting
paraphernalia among this group. The average age of participants was 30 years with an average of 
8 years’ drug use (average length of injecting was 5 years). The information was collected using 
a highly- structured interview schedule administered by one interviewer. According to Speed (1998), 
the most frequently-shared piece of injecting paraphernalia was the spoon. More than two thirds of 
the sample indicated that they use spoons at the same time as someone else, with almost 80% doing 
this on more than one-in-two injecting episodes and with multiple associates over the last four weeks.
Over a third of the sample indicated that they had used the spoons after someone else with over a 
half reporting that they had lent spoons to others. Nearly two thirds of this group lent them to multiple
users including casual acquaintances.
Nearly two thirds of the sample (Speed, 1998) reported that they had used a pot of water at the same
time as someone else, mostly with multiple partners, including casual acquaintances. In contrast, less
than 10% of the IDUs reported using a syringe and needle after another person. Of these eight, seven
participants washed the syringe and needle before they used it. A total of 24% reported allowing
others to borrow a used syringe after them. This study suggests that NEPs are successful in reducing
the risk of sharing needles and syringes, but have not made a significant impact on the sharing of other
injecting paraphernalia. 
A pilot study by Gaskin, Brazil & Pickering (2000) highlights the value of providing sterile water 
and filters to IDUs to meet their basic and important needs. This study examined 40 IDUs at four
Worcestershire Community Drug Team Centres. The majority of participants were male with a mean
age of 30 years. The majority of participants injected heroin. 
The study was interested in ascertaining the behaviours and tendencies towards sharing of injecting
paraphernalia within this group. All participants were administered a questionnaire with 90% reporting
some form of sharing with either a filter and/or water. Only 10% stated that they had never shared at
all. In contrast with other studies, Gaskin et al. (2000) did not differentiate between the person with
whom they were sharing. 
According to Gaskin et al. (2000), environmental factors such as the communal use of water and filters
in drug users’ settings can be clearly identified as potential sources of infection. Despite attending
NEPs, the majority of respondents engaged in risky sharing behaviour of injecting paraphernalia
including water and filters. Although users were aware of the risks associated with sharing equipment,
including HIV, HCV and HBV, they continued to engage in risky behaviours. This finding suggests that
within NEPs, it is necessary to target both changing behaviours and perceptions around risk. Gaskin et
al. (2000) recommend that services should provide sterile water and filters to IDUs, as well as promoting
information about the shared use of paraphernalia. Providing both the equipment and the education is
an essential aspect of harm reduction strategies. 
Factors that Influence Sharing of Drug-Taking Paraphernalia 
Internationally, the most frequent characteristics associated with syringe borrowing include youth 
(e.g. Cassin, Geoghegan & Cox, 1998; Saxon, Calsyn & Jackson, 1994), shorter injecting history 
(e.g. Stark, Muller, Wirth et al., 1995) and being in a sexual relationship with another IDU (e.g. Saxon 
et al., 1994; Gossop et al., 1997).
Key Points
■ All drug-taking routes that require the use of equipment increase the risk of the transmission 
of HIV, HBV and HCV
■ Harm reduction messages around sharing should include discussion about both ‘borrowing 
and lending’
■ Bacterial and viral infections may be spread by contaminated spoons, water or solvent and filters
■ Characteristics most frequently associated with the sharing of equipment include youth, a shorter
injecting history and being involved in a sexual relationship with another IDU
■ NEPs have been successful in reducing the risk of sharing needles and syringes, but have not 
made a significant impact on the sharing of other injecting paraphernalia
■ Within NEPs it is necessary to target both changing behaviours and perceptions around risk
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Chapter 4
Needle Exchange Programmes 
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Much of the activity of harm reduction takes place in the context of NEPs. This chapter is concerned
with NEPs as a harm reduction strategy. The range of settings where NEPs operate is reviewed. 
Definition
In the research literature, the terms NEPs and SEPs are used interchangeably to describe a form 
of harm reduction mainly concerned with risks to IDUs associated with sharing equipment. These
programmes operate on a ‘knowledge and means’ model of behaviour change. It is assumed that in
order to change behaviour, people need to know why such changes are necessary and importantly,
need to be provided with a means to changes in their lives (Homans & Aggleton, 1988). 
Injectors frequently report sharing needles and syringes because of difficulties in accessing this
equipment. This is particularly the case where laws prohibit possession of equipment, or conditions
where needles and syringes are unavailable such as late at night or while in prison (Riley, 1993). As 
IDUs are at risk of infection due to choices such as sharing injection paraphernalia, access to sterile
paraphernalia is vitally important for reducing the risk of disease transmission (Rich, Macalino,
McKenzie et al., 2001). 
International Needle Exchange Programmes 
In the summer of 1984, the Amsterdam Junkiebond, a drug users’ advocacy group, began exchanging
needles and syringes with the support of the Municipal Health Service. Despite having the opportunity
to buy needles and syringes in pharmacies, Junkiebond became concerned that a decision by a
pharmacist not to sell needles and syringes to drug addicts would result in an outbreak of HBV. The
Municipal Health Service delivered needles and syringes in large quantities to Junkiebond once a
week. Two years later, the Municipal Health Service introduced the exchange of needles and syringes
on methadone buses. Between 1985 and 1988, the number of exchanged needles and syringes rose
from 100,000 to 720,000 (Buning, 1991). This increase paralleled a changing awareness of the risk of
acquiring HIV through sharing paraphernalia (Marlatt, 1996). 
The first syringe exchange in the UK opened in 1986 in the Mersey Region Drug Training and
Information Centre. The original location was a toilet cubicle. A review by Stimson (1998) estimated
that there were about 450 NEPs and pharmacy exchanges in the UK with a total of 2,000 outlets. In
addition, syringes and needles are sold through pharmacies. In London, about 75% of injectors obtain
their equipment from NEPs and pharmacy exchange schemes. Anderson et al. (2003) report on the
contribution that community pharmacies have made to needle exchange programmes. According 
to their report the number of pharmacies providing needle exchange services increased from 3.0% 
in 1988 to 18.9% in 1995 along with an increase in the sale of injecting equipment to 34.5% from a
previous recorded figure of 28% in 1988. A number of factors are associated with community pharmacy
participation in these services, (male gender; more recent registration; and a positive attitude towards
drug misuse). Their findings conclude that pharmacy-based needle exchange schemes are cost
effective and that specific training needs of pharmacists participating in these schemes have been
identified. 
The success of pharmacy-based needle exchange in Great Britain can be associated with how these
services are standardised and audited by the Royal Pharmaceutical Society of Great Britain. The
Society’s functions include regular inspection of pharmacies to monitor standards of practice and
compliance with legal and professional requirements (Flint, 2001). Sheridan et al. (1996) reviewed the
role of community pharmacies in relation to HIV prevention and drug misuse. The authors found a
substantial increase in the overall contribution of community pharmacies to the provision of services 
to drug misusers. This included the emergence of pharmacies with more specialised involvement with
drug misusers, including an extensive network of points of contact for drug misusers, not all of whom
will take part in formal treatment programmes. 
In Switzerland, syringes and needles have been available through contact centres, vending machines
and outreach workers since the 1980s. A consequence of this has been a recorded decrease in HIV
transmission amongst IDUs. The Swiss Federal Office of Public Health (1999) acknowledges that efforts
to control the spread of hepatitis are required. Understanding the risks associated with sharing
injecting paraphernalia and implementing appropriate measures to minimise the risks may assist in
addressing this problem.
While government-funded NEPs are well established in several countries, there has been strong
opposition to this in the US. Federal funding has been prohibited until the Surgeon General
determines whether NEPs would be effective in preventing the spread of HIV and would not promote
the use of illegal drugs. State legislation relating to prescription and paraphernalia laws restricting
possession and distribution of needles and syringes hinder the operation of NEPs. 
By 1994, 55 US cities had established NEPs, many operating illegally on a small scale and with minimal
funding (Hurley & Jolley, 1997). A key aim of NEPs, to prevent the spread of blood-borne infections,
has been promoted through the reduction of the incidence of HIV by approximately 70% in New York
City (Des Jarlais & Michael, 1996).
Canada’s first official NEP opened in Vancouver in 1989. Over 100 Government-sanctioned exchanges
have opened in Canada (Conley, Hewitt, Mitic, et al., 1998). In Canada, NEPs operate from fixed sites,
mobile exchange vans that provide needle exchange throughout the night, and pharmacies (Wood,
Tyndall, Spittal et al., 2002; Conley et al., 1998). IDUs are informed about the locations of NEPs through
flyers and adverts at the fixed sites, at other IDU services and through word of mouth. 
In Australia, the first pilot and illegal NEP were established in 1986. A year later, a government-funded
NEP was established in New South Wales (Loxley, 2000). In line with other countries, injecting
paraphernalia can be obtained from both NEPs and pharmacies. Few NEPs insist on one-to-one
exchange. Exchange can be facilitated by providing free equipment for used equipment and charging
at a cost-recovery rate for non-exchanged equipment (Loxley, 2000). 
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NEPs operate in Australia from fixed sites, dispensing machines and through the ‘Fitpack’ programme.
This programme operates through community pharmacies in Western Australia. It does not include an
exchange component but provides needles and syringes with a safe disposal container (Lenton et al.,
2000). Five needles and syringes were sold in each Fitpack. These hard plastic containers are designed
to enable used syringes to be ‘locked-in’ for disposal so that they cannot be reused or cause harm 
to others. 
Harm reduction, as well as providing the drug misuser with sterile drug-taking paraphernalia through
NEPs, places emphasis on communicating with the individual and engaging them in health care
services and much of this activity takes place through NEPs. Services aim to be effective in the
reduction of the transmission of HIV, HBV and HCV. The literature reveals that NEPs combine the
exchange of paraphernalia and the delivery of information, providing essential communication with the
drug misuser. However, pragmatic approaches to NEPs recognise that personal contact is not always
feasible, and in these incidents, services have been augmented with NEPs through vending machines. 
Key Points
■ NEPs are established internationally as a key component of harm reduction strategies, which
provide clean paraphernalia, advice and education to drug misusers
■ NEPs operate from a range of fixed sites, mobile units and vending machines
■ Pharmacy-based NEPs are cost effective and provide an extensive network of contacts for drug
misusers, not all of whom take part in formal programmes
■ NEPs have been positively associated with a decrease in the transmission of HIV 
Chapter 5
Service-Supervised Drug-Consumption Rooms
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International developments in harm reduction services have in some countries included the provision
of supervised drug-consumption rooms. Limited trials providing heroin to users have been conducted.
In this chapter the introduction of consumption rooms for drug misusers is considered. Heroin
provision is discussed. Harm reduction interventions and treatment measures that extend to the
provision of environments where drug misuse is facilitated and where scheduled drugs are part of 
trials or provided as treatment have both national and international legal implications. These legal
implications are addressed in chapter 10. The provision of naloxone as a harm reduction strategy is
also discussed.
Within the literature a number of terms are used, some times interchangeably, to describe facilities
where drug users congregate to take drugs. These terms include drug-consumption rooms, safe-
injecting facilities, safe-injecting rooms and medically-supervised injecting centres (EMCDDA 2002a,
Nadelmann et al., 1999, Mattick et al., 2001). Consumption room normally refers to supervised 
safe drug-taking facilities for the administration of drugs, which are provided by statutory or state-
recognised, agencies. Supervision is provided by trained staff operating as part of a multidisciplinary
team. Consumption rooms aim to reduce harm both for the drug user and the wider community 
(Hunt et al., 2003). A number of benefits to the drug user are suggested including the prevention of
HIV, HBV and HCV, facilitation of access to treatment, the provision of social support and reintegration,
along with reductions in overdose and venous damage. The community at large may also benefit from
reduction in drug related litter of needles and syringes and public injecting. 
Distinctions need to be made between service-supervised consumption rooms and shooting galleries.
The term shooting gallery normally refers to an unsupervised place where drug users congregate to
take drugs. Consequently, they do not always adhere to best practice in relation to harm reduction. 
Service-Supervised Consumption Rooms
Safe injection facilities are part of the harm reduction approach in the Netherlands (Mol & Trautman,
1991), Switzerland (Klingemann, 1996), Germany (de Jong & Weber, 1999) and Spain (Kimber et al.,
2002). A study by Kimber et al. (2002) identifies 39 supervised injecting centres in the Netherlands,
Switzerland, Germany and Spain. A similar facility has been established in Australia on a trial basis
(Dolan, Kimber, Fry et al., 2000). The Sydney trial is one of only 59 equivalent drug consumption centres
operating in 33 cities in Germany, Switzerland, the Netherlands and Spain (Burton 2003). Two further
European countries, Portugal and Luxembourg, are planning similar facilities. The EMCDDA annual
report (2002b) shows that Norway and Denmark considered and decided against the introduction of
supervised consumption rooms. 
The goals associated with the introduction of safe injection facilities depend on the setting in which
they have been introduced. Goals include the reduction of the incidence of infectious disease
transmission, to improve the general health of IDUs and to increase their use of appropriate primary
health care and social services (Kerr & Palepu, 2001). 
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Safe injecting facilities achieve the goals of harm reduction by supervising injections in a controlled
setting, ensuring safety and quick responses to overdoses, providing sterile injecting equipment and
condoms, collecting used needles and syringes and providing counselling and primary health care
(Kerr & Palepu, 2001). Safe injecting facilities are a means of increasing contact with the most
marginalised IDUs (Mol & Trautman, 1991). Safe injecting facilities use a humanitarian approach and
function on a background of medical ethics (reducing mortality, reducing morbidity, alleviating the
suffering, trying not to damage the patient by the measures taken) (Haemmig 2003). 
Hagen (2002) describes the challenges in estimating the contribution of supervised injecting rooms 
to harm reduction for drug users. Safe injecting rooms represent a relatively small segment of public
health activities in communities where they exist, and the proportion of users who participate in safe
injecting rooms may be smaller than the proportion utilising needle exchange or drug treatment. This
limits the possibility of finding a community-level effect of the programme, and relatively large samples
of drug users would be needed to detect any association between the use of safe injecting rooms and
reduction in overdose or transmission of blood-borne viruses (Hagen 2002). “The attempt to show the
benefit of safe injecting facilities by scientific research is a difficult task… it is impossible to create a
potential control group, because drug users are mostly a hidden population” (Haemmig 2003). 
Consumption Rooms and Relevant Policy
De Jong & Weber (1999) refer to ‘consumption’ rooms rather than injection rooms as drugs may be
inhaled, consumed orally or injected. In the Netherlands, the city administration is legally responsible
for policies on health promotion and public order enforcement. Local government carries the
responsibility for the development, functioning and financing of drug consumption rooms. They are
known as ‘facilities to be tolerated’. In Germany and Switzerland, it is also local government that takes
responsibility to develop policy in this field. There is an identifiable conflict between law reform and
public health issues. The Netherlands policy of ‘facilities to be tolerated’ should not be misinterpreted
as legislation that legalises the consumption of drugs but as a pragmatic approach to harm reduction. 
Hunt et al. (2003) state that the organisation of consumption rooms and the emphasis within their
objectives varies according to the setting in which they are provided. For example the medically-
supervised centre in Sydney Australia was introduced against a context of high levels of heroin
overdose. The centre, based in the inner city district of Kings Cross, opened on a trial basis following
the passing of appropriate legislation by the state government of New South Wales. Yamy (2000) 
stated that the International Narcotics Control Board accused the state of New South Wales of
violating international treaties on narcotics. A spokesman for the board said: “Any nation state or local
authority that permits the establishment and operation of such drug injecting rooms also facilitates
illicit drug trafficking” (Yamy, 2000). In the Netherlands where rates of injecting and overdose are
comparatively low, there is greater emphasis on reducing the nuisance from street drug use and
providing social support within a more informal setting (Hunt et al., 2003). 
The role that drug consumption rooms play in the prevention of death following heroin overdose has
been given much consideration. Research on the association between supervised injecting rooms and
drug overdose is encouraging but not definitive (Hagen, 2002). Burton (2003) reports that in the period
May 2001 to October 2002, 3810 registered individuals made 56,861 visits to Australia’s first medically-
supervised injecting centre. A total of 409 incidents of drug overdose were recorded, though none
were fatal. No overdose deaths have occurred among hundreds of thousands of Swiss and German
supervised injectors (Sporer, 2003). 
However positive this management of overdose appears, there are other points to consider about 
the impact of supervised consumption rooms on injecting drug users. Christian (2003), reporting 
on Australia’s medically-supervised injecting centre, highlights that clients average a maximum of 7
injections at the centre out of every 100 and that only 4.1% of overdoses in Australia are fatal. Byrne
(2003), who supports the centre, is not surprised that drug misusers continue to inject elsewhere as the
centre is only open for 8 to 12 hours daily. Other harm reduction targets are also examined by Christian
(2003) in relation to the introduction of the centre. No improvement was recorded in ambulance
overdose attendance in the area outside or during the hours the centre was open. No statistical
improvements were recorded in HIV and HBV infections. Despite the presence of the injecting room,
HCV was worse by 11% per year in line with the HCV epidemic trend Australia wide. Regarding new
needle and syringe use – the injecting room displayed no advantage over the nearby needle exchange
and no improvement in the reusing of someone else’s syringe (Christian, 2003). 
The recent ‘heroin epidemic’ has led to a dramatic increase in the incidence of fatal and non-fatal
overdose in many countries (Sporer 2003). Death from opiate overdose increased 55-fold in Australia
between 1964 and 1997 and heroin overdose was the leading cause of death among men aged 25-54
in Portland, Oregon in 1999. Every year 2% of people who inject heroin die, which is 6-20 times the rate
expected in peer controls of those who do not use drugs (Sporer 2003). Most of these deaths occur in
the company of other people and medical help is not sought until it is too late. 
Naloxone Provision
Another strategy employed to prevent or minimise the risk associated with heroin overdose is making
naloxone available to drug users. Naloxone is a specific opiate antagonist2 with no agonist properties
and no euphoriant potential. It has shown to be very effective in treating acute overdose. Naloxone 
has been sold over the counter in Italy for more than 10 years and has been distributed through NEPs
since 1995 (Simini, 1998). Home naloxone programmes have commenced in Germany and England,
New Mexico recently adopted legislation allowing the distribution of home naloxone as well as
expanding the categories of public safety personnel allowed to use it and the Chicago recovery
alliance have provided 550 drug users with naloxone (Sporer, 2003). Sporer (2003) highlights that
distributing naloxone could be interpreted as condoning heroin use, as well as making it seem safer 
to use heroin in even larger dosages. 
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2 Antagonist – completely reverses the effect of opiates.
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Provision of Safe Injecting Environments
In a prospective cohort study of 1400 IDUs in Vancouver, Wood, Tyndall, Spittal et al. (2001), analysed
data on 776 participants who reported injecting drugs during the 6 months prior to follow up. Of this
group, despite a large NEP in Vancouver, 28% of the IDUs reported sharing needles. Pharmacy refusal
to provide sterile needles and requiring help in injecting were positively associated with sharing
needles. Univariate analysis of drug use and behavioural characteristics indicated other factors that
were positively associated with needle sharing. These included difficulty getting sterile needles and
frequency of injections. A total of 19% of the sample reported sharing needles despite having easy
access to them. This finding suggests that the expansion of the NEPs on its own is not sufficient to
eliminate the risks associated with sharing equipment (Wood et al., 2001). Being older and HIV positive
was inversely associated with needle sharing. Wood et al. (2001) emphasise that HIV testing and
counselling, health and social functioning, and drug addiction treatment have occurred among clients
of safer injecting rooms where they exist. A converse incidence of HIV risk behaviour, including
reduced needle sharing and hospital admission, improved needle disposal, a decrease of drug
injecting in public places and a reduction in death from overdose, has resulted.
In several European cities, the risk factors identified by Wood et al. (2001) have been addressed
through the establishment of safer injecting rooms as part of comprehensive harm reduction strategies
(Dolan et al., 2000). Smyth et al. (2001) identified that syringe borrowing persists amongst IDUs in
Dublin despite the existence of harm reduction programmes and recommends that interventions
should include exploring the unique attitudes and beliefs regarding unsafe injecting with each
individual. Supervised consumption rooms may provide another point of access to services for
marginalised Irish IDUs. The findings of Dolan et al. (2000), Smyth et al. (2001) and Wood et al. (2001),
all suggest that NEPs on their own are not sufficient to eliminate the risks associated with sharing drug-
taking paraphernalia. 
Heroin Provision
Pharmaceutical heroin (diamorphine) provision has been considered and trialed as a treatment
approach to IDUs. The arguments for such an approach include, attracting people who might not 
be inclined otherwise into treatment, reducing illicit drug use, undercutting the black market and
protecting the physical health and social functioning of the IDUs. Counter arguments include that 
it maintains the IDUs in their current position of drug use and may postpone by years eventual
abstinence from heroin. It may increase the number of IDUs continuing to inject. It could be considered
contrary to harm reduction principles in that prescribing injectable opiates might be associated with 
an increased incidence of deep venous thrombosis as a consequence of injecting into the femoral
veins following loss of venous access in the arms (Zador, 2001). It is more costly than the provision of
oral substitution drugs such as methadone. In the UK, heroin has been used to treat addicts since the
1920s (Hunt et al., 2003). Despite the concerns about such an approach proposals for heroin trials in
Australia and more recently Denmark, Luxembourg and the Netherlands have followed from perceived
successes elsewhere. Hunt et al. (2003) reports that the proposed Australian trial did not commence, 
as their government did not sanction it. Similarly Germany, France, Belgium, Spain and Canada are
planning or currently taking part in trials of heroin prescription (Hunt et al., 2003). 
The UK differs from most other countries by including injectable heroin and methadone in its range 
of opiate substitution therapies for heroin-dependent users (Zador, 2001). A small number of licensed
medical practitioners can prescribe heroin to any drug-dependent user following assessment of their
suitability for this intervention. Heroin provision became part of practice in the United Kingdom in 1926
following the Rolleston report. In the 1970s oral methadone became the predominant form of opiate
maintenance treatment. This shift was in response to data emerging from the United States and the
result of local research (Zador, 2001). Currently, the option of injecting opiate treatment is infrequently
exercised – less than 1.7% of all prescriptions for treatment of opiate dependence are for heroin, while
injectable methadone accounts for about another 9%. 
The few studies that have evaluated heroin maintenance in the UK reported reduced levels of crime
among heroin-maintenance patients as measured by self-reporting (Zador, 2001). Hall (1999) suggests
that for heroin maintenance to have an impact on the negative social consequences of dependent
heroin use such as crime, would require, among other conditions, a substantial scaling up in provision
of this treatment. McClusker & Davies (1996) in their study on prescribing the drug of choice to illicit
heroin users found that those who remained in oral methadone treatment showed a reduction in
prescribed opiate use and more were aiming at abstinence as a goal compared with the group
receiving prescribed heroin. In their 1977 study, Thorley, Oppenheimer & Stimson found that at a 6-year
follow-up of 128 patients prescribed heroin, only 23% had remained continuously in treatment over this
time period. More data are needed on long-term outcomes of both injectable heroin and methadone
to assess whether patients are more likely to remain in injecting opiate treatment than transfer to oral
methadone treatment and/or become abstinent (Zador, 2001). The British model of injecting opiate
treatment is unique and has attracted much attention. Reference is made to it in both the Swiss and
Dutch trials. Britain’s paucity of evaluation of this intervention is all the more mystifying given its
controversial status (Zador, 2001).
In 1992 in Switzerland, an evaluation of heroin, methadone and morphine prescribing involving 1035
users was conducted (Uchtenhagen et al., 1999). A total of 17 outpatient treatment centres and one
prison were involved in this project. Strict admission criteria to the project were outlined. Users were
receiving 500 to 600 mg of heroin daily. The injections of the prescribed drugs had to be given under
strict supervision and these could not be taken home. Heroin was prescribed as part of a
comprehensive social and psychological intervention.
During the study, 11 people who previously tested negative, tested positive for HIV (N=3), HBV (N=4)
and HCV (N=5)*. The researchers concluded that this could be related to cocaine injecting outside the
programme. Illicit heroin and cocaine use rapidly and significantly decreased, benzodiazepine use
decreased slowly and alcohol and cannabis consumption hardly reduced. Income from illegal activities
decreased dramatically. By the end of the project, 8% decided to give up heroin and sought
abstinence therapy.
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The heroin provision in prison required operational changes within the system as well as changes in
staffs’ attitudes. Positive outcomes were identified overall and it was noted that good collaboration
with outpatient treatment centres could be established for follow-up treatment of discharged inmates.
Uchtenhagen et al. (1999) concluded that heroin-assisted treatment can be carried out safely and 
that significant health and lifestyle improvements can be obtained and maintained post treatment.
Retention in treatment was 89% at six months and 69% at 18 months (Uchtenhagen et al., 1999). 
They state that the economic benefit of such programmes is considerable particularly in relation to 
a reduction in costs of criminal procedures and disease treatment. The cost of this trial needs to be
considered. 
At the request of the Swiss Government and the International Narcotics Control Board (INCB) the
WHO co-ordinated an evaluation of the Swiss heroin prescribing project (Uchtenhagen et al., 1999). 
A three-stage evaluation was conducted examining the study protocol, the implementation of the
project and a review of the scientific report. Ali et al. (1998) reported that the prescription of injectable
heroin is feasible, clients can be maintained on a stable dose of heroin, heroin treatment programmes
can be delivered at treatment centres providing methadone maintenance with some modifications, 
the programme achieved reasonable retention levels and individuals self-reported improvements in
their physical and mental health, social function, drug use and criminal behaviour. 
However Ali et al. (1998) also reported that the Swiss study was not able to examine whether
improvements in health status or social function was causally related to heroin prescription per se or as
a result of the impact of the overall treatment programme. From a rigorous methodological viewpoint,
it is not possible to obtain internally-valid results with respect of the research question of heroin
prescribing being causally responsible for improvements in health status or social function of the
individuals treated (Ali et al., 1998). The study has not provided convincing evidence that, even for
persistent methadone failures, the medical prescription of heroin generally leads to better outcomes
than further methadone treatment. The knowledge base is not large enough to determine cost
effectiveness and the differential indications for heroin substitution treatment. 
There are many limitations to this trial including the absence of a comparison group and the social,
cultural and political context within which this programme was introduced. These need to be
considered in any replication of this trial. Switzerland have now authorised the prescription of heroin
for opiate dependence (Hunt et al., 2003). The scale of the Swiss trial needs to be considered. The
treatment described has only assisted about 3% of Swiss heroin addicts in the long term (Copeman,
2002). However, a wider programme would inherently be more difficult to monitor – to see that addicts
actually receive the treatment – and it might send entirely different signals to new or prospective
addicts, who could well see prescription heroin as an easy option to take up (Copeman, 2002). 
It is important to acknowledge that these recent Swiss studies made no attempt to investigate the 
long-term effects of the prescription of heroin alone, i.e. without obligatory counselling and other
psychosocial interventions. Thus they do not provide information about the effect of the prescription 
of heroin per se, but rather about the effects of a combined package of pharmacological (heroin) and
psychosocial interventions (Van Den Brink et al., 1999). Wodak (1998) comments on the difficulties of
disentangling the contribution of comprehensive social and psychological interventions in the
impressive results obtained in the Swiss trial. After more than three decades of research evaluating 
the effectiveness of methadone maintenance treatment, it is safe to conclude that such an intervention
improves outcomes but it is difficult to be much more precise than this. Social and psychological
interventions probably improve results of virtually all interactions between patients and the healthcare
system (Wodak, 1998). 
Sendi et al. (2003) report on intravenous opiate maintenance in a cohort of injecting drug addicts in
Switzerland. They are especially concerned with injecting drug addicts who have repeatedly failed
withdrawal or substitution treatments on the basis that this group of patients according to Belding
(1998) consume more cocaine and heroin and are often not willing to quit substance abuse. The 
opiate maintenance programme was started as a prospective cohort of patients who were treated
intravenously with heroin, morphine or methadone. An important aim of this programme is to keep 
the patients as long as possible under medical supervision in order to reduce the health hazards
associated with illicit drug consumption (Rehm et al., 2001). Patients were included in the program
when the following conditions were met: a history of intravenous heroin consumption of at least 2
years; previous failed withdrawal treatments; health problems associated with drug consumption; and
an age of at least 20 years (Sendi et al., 2003). A total of 175 patients were included in the study. The
majority of patients were 21-years old. There were a total of 76 treatment withdrawals. The three-year
probability of remaining in the study was 61.7% (Sendi et al., 2003). 
There were 134 HIV negative patients at the start of the study and only one seroconversion was
observed during the study period. The first patient entered the programme in 1994 and the last patient 
in 1996. Patients were followed up until autumn 1998. There were 37 HBV negative patients at study
entry and six seroconversions during the study. There were 30 HCV negative patients at study entry 
and seven patients seroconverted during the study period. HIV, HBV and HCV were not associated 
with time-to-treatment withdrawal. The longer than usual follow-up period in this study is important.
One of the objectives of prescribing injectable heroin is to reduce criminal behaviour associated 
with illicit drug use. However 14% of treatment withdrawals (6% of the study population) were due 
to violence or threat. The risk of treatment withdrawal was independently associated with age and
duration of injecting use (Sendi et al., 2003). No control group was used, and the authors did not
control for psychosocial factors such as marital status, poverty and homelessness. The authors found
that individuals with a longer injecting history, and of a younger age, were more likely to withdraw from
the programme. 
Heroin can be prescribed in the Netherlands for research purposes. An experiment involving the
prescription of heroin under strict medical supervision began in the Netherlands in 1998. It involves a
group of 750 users who it was considered could no longer be helped by the regular care system. The
outcomes are being compared to a treatment group with methadone and a treatment group with a
combination of heroin and methadone. The aim of the study is to examine whether the prescription 
of heroin has a beneficial effect on the physical and mental health and on social functioning of the 
user (cited in NDS 2001). 
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Van Den Brink (2003) reports on two randomised controlled trials of the medical prescription of heroin
to treatment-resistant heroin addicts. 549 participants took part in two separate, open label, multi-
centre, randomised controlled trials and five treatment groups; three in the inhaling trial and two in 
the injecting trial. At the end of 12 months, participants in the control groups were offered six months
of medically-prescribed methadone plus heroin. In all cases the medically-prescribed heroin was
discontinued for at least two months after the end of the experimental period. All patients had full
access to standard medical and psychological services. Twelve-month follow-up data was available 
for 93-94% of the randomised participants. Completion rates were high in all treatment groups, but
somewhat higher in the group allocated methadone alone than in the group allocated to heroin plus
methadone. The experimental treatment with 12 months of methadone plus heroin was significantly
more effective than 12 months of heroin alone, both in the inhalation trial and in the injecting trial.
Treatment response showed clinically-relevant improvements in all outcome domains. These changes
were absent in non-responders, with the exception of a reduction in illegal activities in the participants
who received heroin in addition to methadone. Many (82%, N=94) of the treatment responders in the
experimental group deteriorated substantially in the two months after the planned discontinuation 
of the co-prescribed heroin, returning to the scores seen just before the start of the intervention on 
the multi-domain outcome index. In the two trials supervised, medical co-prescription of heroin to
treatment-resistant heroin addicts was more effective and probably just as safe as methadone alone
(Van Den Brink et al., 2003). Van Den Brink et al. (2003) state that the most important advantage of 
their study is that the observed effects of the co-prescription of heroin could not be attributed to a
difference in the offer of psychosocial treatment between the experimental and the control group. This
finding is important in relation to the Swiss trial where the impact of psychosocial interventions is not
clarified. Limitations of this study include that a double-blind design is not employed and self-reported
outcome data is exclusively employed. 
Heroin provision, where it has been trialed, has been limited to particular patient groups. The UK
Department of Health (1999) recommend that injectable opiates should only be given to patients with
long, complicated and intractable histories of opiate dependence, and/or who have failed other forms
of treatment. The Netherlands trial involves a group of drug misusers who it considered could no
longer be helped by the regular care system. The effectiveness of heroin maintenance demonstrated
under the conditions of clinical trials may not be replicated if the same degree of quality is not
maintained in its scaling up (Hall, 1999). Injecting prescribed opiates per se does not reduce the risk of
blood-borne infections among injecting drug users, rather, it is the use of clean needles, syringes and
other equipment to inject heroin, prescribed medications or any other drug (Zador, 2001). Zador (2001)
states that until a consistent and substantial body of data is accumulated supporting sustained positive
outcomes of injecting opiate treatment for both the individual patient and the community, the harm
minimization benefits of long-term, injecting opiate treatment can only be speculative, however
plausible the arguments seem. 
There is insufficient evidence on the effectiveness of heroin as a treatment. Ferri et al. (2003) state 
that no definitive conclusions about the overall effectiveness of heroin prescription are possible
because of non-comparability of the experimental studies available. Results favouring heroin 
treatment come from studies conducted in countries where the treatment system is comprehensive
and easily-accessible, methadone-maintenance treatment at effective dosages is available (Ferri 
et al., 2003). This is due to the limited amount of trials that have taken place. Hunt et al. (2003)
catalogues that 4 small-scale trials have taken place in the UK between 1980 and 1998. One large trial,
discussed above, has taken place in Switzerland, along with two trials in the Netherlands. Randomised 
controlled trials to date have been limited to four, the 1980 UK study, the Swiss study in 1998 and 
two large studies in Holland. Differences exist in the administration of these trials. In the UK studies,
where the law permits the prescription of heroin, supervised consumption has not been part of the
trial, as participants are given the drug to take home. There is little evidence that current prescribed
heroin is diverted onto the illicit market but historically this was significant (Hunt et al., 2003). Both 
the Swiss and Dutch studies involved supervised consumption so the diversion of the drug to others 
is not an issue.
Key Points
■ Maintenance of heroin drug users on methadone reduces the incidence of fatal and non-fatal
heroin overdoses 
■ The goals associated with the introduction of supervised consumption rooms include the reduction
of the incidence of infectious disease transmission, an improvement in the general health of IDUs
and the increase of their use of appropriate primary health care and social services
■ Supervised consumption rooms were established as a way of increasing contact with the most
marginalised IDUs
■ Introduction of supervised consumption rooms as part of a harm reduction strategy needs to give
careful consideration to the context in which they are being introduced and to the required
amendments in state legislation 
■ A limited number of trials have taken place on prescribing heroin; more research is required in 
this area
■ Heroin trials have not fully examined whether improvements in health status are causally related 
to heroin prescription or as a result of the impact of the whole programme
■ The knowledge base on heroin trials is not large enough to determine cost effectiveness and the
different indications for heroin substitution treatment
■ Injecting prescribed opiates does not reduce the risk of blood-borne infections, it is the use of
clean drug-taking paraphernalia that achieves this harm-reduction aim 
A
 R
e
vie
w
 o
f H
arm
 R
e
d
u
ctio
n
 A
p
p
ro
ach
e
s in
 Ire
lan
d
 an
d
 E
vid
e
n
ce
 fro
m
 th
e
 In
te
rn
atio
n
al Lite
ratu
re
N
A
C
D
 2
0
0
4
31
Chapter 6
Reducing Transmission of HIV, HCV and HBV
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As outlined in previous chapters, harm reduction focuses on minimising the personal and social harms
associated with drug use including the spread of blood-borne diseases such as HIV, HCV and HBV. This
chapter of the report examines research on the effectiveness of harm reduction strategies specifically in
relation to the transmission of HIV, HBV and HCV. 
Studies demonstrate that NEPs reduce the transmission of HIV through the provision of drug-taking
paraphernalia (e.g. Des Jarlais & Michael, 1996). It has also been demonstrated that NEPs provide IDUs
with opportunities to engage with a variety of health care services such as counselling and referral to
drug treatment programmes (Strathdee, Currie, Patrick et al., 1999). This engagement is facilitated
through interaction with health care workers.
Implications of Sharing Drug-Taking Paraphernalia
The shared use of injecting paraphernalia carries a risk of infection from viral material remaining 
on injecting equipment after use (Chitwood, McCoy, Inciardi et al., 1990). Front- and back-loading
increases the risk of HIV transmission by directly placing blood within the needle-syringe (Shapshak,
Fujimura, Page et al., 2000). Front- or back-loading is the process of transferring a drug solution from
one syringe to another (Office of National Drug Control Policy, 2003). Although new needles and
syringes may be used, bacterial and viral infections may be spread by contaminated paraphernalia 
such as spoons, water, solvent or filters (Caflisch & Wang, 1999).
Gossop et al. (1997) found participants were least likely to report receiving syringes from casual
acquaintances. As discussed above, IDUs in their study were more likely to report lending compared to
borrowing syringes. This effect was not found for spoons and water containers, the receiving of which
was treated in a less discerning manner. Back-loading was frequently reported by more than a third of
the sample, with almost half of these reporting that they used the syringe of a casual acquaintance.
Gossop et al. (1997) suggested that this might be seen as a less ‘intimate’ form of sharing, appropriate
to engage in with a casual acquaintance, whereas needle sharing is perceived as being risky. 
Almost one third of this sample tested positive for anti-HBV (HCV levels were not reported) and less
than one percent tested positive for HIV. Gossop et al. (1997) concluded that it is possible that the
sharing of injection equipment other than needles and syringes may be directly related to the high
rates of HBV among IDUs. 
Their findings may reflect the preventive messages about ‘needle sharing’. The risks associated with
the sharing of spoons and water have been largely ignored within these harm reduction messages.
Gossop et al. (1997) recommend that detailed information warning about the sharing of paraphernalia
should be included in harm reduction messages. 
Hepatitis C
HCV, like HIV, is a blood-borne agent and is spread through the sharing of infected needles, cookers,
spoons, other injecting paraphernalia and through front- and back-loading of drugs (Garfein, Vlahov,
Galai et al., 1996; Van Beek, Dwyer, Dore et al., 1998). Unlike HIV, HCV is efficiently transmitted among
IDUs (Pollack, 2001). The research suggests that treatment and prevention interventions are less
successful in preventing HCV compared to HIV (Coutinho, 1998). 
Hope, Judd, Hickman et al. (2001) found that anti-HCV prevalence rates among IDUs in England and
Wales where comprehensive harm reduction programmes exist are lower in comparison to rates in
other industrialised countries. Amongst those who had injected for less than two years, the prevalence
of anti-HCV was 30% and the annual incidence of HCV infection was estimated to be 5%. In cross-
sectional studies it is difficult to provide conclusive proof that estimated prevalence and incidence have
decreased. Hope et al. (2001) recommend that prevalence and incidence of anti-HCV in IDUs with short
injecting careers be monitored for a number of years.
Range of Services that Address HIV and HCV Risk Behaviour
Services that aim to reduce HIV and HCV risk behaviour in IDUs include health education, NEPs,
prescription and administration of replacement drugs, provision of safer-sex education and easier
access to free condoms. NEPs have been widely promoted as a harm reduction strategy for IDUs and
now operate in many locations throughout Europe, North America, Australia and Asia. Traditional
services are described as needle and/or syringe exchanges but in many cases a broader range of 
drug-taking paraphernalia is on offer to IDUs. These may include alcohol wipes, citric acid, sterile 
water, spoons or ‘cookers’, filters, and/or bleach. The range of paraphernalia available is dictated by
local policy and current health care trends. 
It has been clearly demonstrated that methadone treatment results in decreased heroin injection,
overall improvement in health status and social functioning, and reduced risk of HIV infection among
opiate addicts (Hartel, Schoenbaum, Selwyn et al., 1995). In addition, providing condoms through
services provides an important link between active IDUs, medical and social services. These services
need to be easily accessible and available if they are to have a positive impact on IDUs.
Persistent High HCV Transmission
Crofts, Aitken, Kaldor (1999) note that despite harm reduction programmes in Australia, HCV continues
to spread. Crofts et al. (1999) studied used injecting equipment from ten injecting settings for the
presence of HCV. HCV was detected on 70% of syringes, 67% of swabs, 40% of filters, 25% of spoons
and 33% of water samples. These figures indicate that HCV is efficiently transmitted via drug-taking
paraphernalia. 
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Speed (1998) writes that legislation in the UK sets targets related to needles and syringes, using these
measures as indicators of success for NEPs. He notes that the sharing of injection paraphernalia has
been largely ignored (Speed, 1998). Crofts & Aitken (1997) suggest that in order to control for HCV, it 
is not enough to promote non-sharing of needles and syringes – other strategies must be encouraged.
These may include encouraging IDUs to use their drugs in ways other than injecting, more intense
concentration on hygiene practices, education, and support of IDUs to avoid sharing any equipment
associated with injecting.
The persistent high rate of the transmission of HCV is a concern for IDUs. The research indicates 
that HCV is a resilient virus and can be spread through sharing the complete range of drug-taking
paraphernalia. The authors suggest that this has implications for those who snort or smoke drugs. 
The literature search generated no published material on the transmission of HCV between users who
shared pipes. No literature was discovered on seroconversion rates of HIV, HCV or HVB in this group.
Considering the resilience of HCV, research in this area is imperative. 
It is evident from this review of the literature that sharing injecting paraphernalia is common and poses
a major risk to the health and well-being of the user as well as having implications for HCV, HIV and
HBV transmission. It is paramount that harm reduction programmes aim to reduce the sharing of all
injecting and drug-taking paraphernalia in order to reduce the risks. The above studies emphasise that
it is not sufficient only to highlight the risks associated with sharing needles and syringes. NEPs need to
stress the risks associated with sharing other injecting paraphernalia.
North America
United States
In 1992, the New York State Health Department permitted the legal operation of 5 community NEPs.
According to Des Jarlais & Michael (1996), these services expanded rapidly exchanging 1.75 million
syringes in 1994. In their study the incidence of HIV in IDUs availing of NEPs in New York was
compared to incidence rates of a group not attending a similar programme. Using meta-analysis, 3
studies on HIV incidences were combined. An individual-level protective effect against HIV infection
associated with participation in NEPs was identified. Des Jarlais & Michael (1996) recommended the
legal provision of sterile injection paraphernalia to reduce the risk of HIV infection in IDUs.
Canada
The continued transmission of HIV and HCV suggests that high numbers of IDUs are still sharing
(Patrick, Tyndall, Cornelisse, et al., 2000). 
The debate over the efficacy of NEPs has been partially fuelled by the experience of Vancouver, where
an increase of 18% in the incidence of HIV among IDUs was reported (Strathdee et al., 1997). The
prevalence of HIV among those who frequently attended the NEP was higher than those who attended
less frequently (Strathdee et al., 1997). This high prevalence rate was attributed to an ongoing and
serious outbreak of HIV infection among IDUs in Vancouver. Expanding NEPs would help to reduce
sharing further; several risk factors remain independently associated with needle sharing after
adjustment for difficulty getting needles (Wood et al., 2001). Having difficulty getting sterile needles,
needing help injecting, reusing needles and frequent cocaine and heroin injection were all associated
with needle sharing. 
Schechter, Strathdee, Cornelisse et al. (1999) conducted a study to examine if NEPs were causally
related to the spread of HIV. They engaged in a prospective cohort study of 694 IDUs in Vancouver 
all of whom were HIV negative at the time of recruitment. At baseline and twice annually, blood tests
were taken for HIV and HCV and participants completed an interviewer administered questionnaire.
Schechter et al. (1999) hypothesised that NEPs per se were not causally associated with HIV
transmission and that the apparent excess risk was due to the fact that the programme attracted
participants who were at higher risk because of their risk behaviours. 
In a systematic review of the effectiveness of harm reduction strategies regarding HCV in Canada,
Leonard, Forrester, Navarro et al. (2001) reported various international studies suggesting that HIV
prevention strategies have been relatively ineffective in preventing HCV. Leonard et al. (2001) included
15 relevant but largely methodologically weak studies. These results suggested that participation in
NEPs or methadone maintenance programmes exerts no protective effect against HCV seroconversion.
In prevention settings where harm reduction measures have contributed to the maintenance of low
prevalence and incidence of HIV, transmission of HCV infection continues at extremely high levels. 
The sharing of drug-preparation equipment such as spoons and other injecting paraphernalia have
been associated with the transmission of HCV.
Australia
In Western Australia the lowest rates of HIV among IDUs in the Western world are found (Lenton, Kerry,
Loxley et al., 2000). However, while HIV rates are low, Australia’s nationwide harm reduction strategy
has been less successful in minimising the spread of HCV and HBV. HCV has a higher average
transmission efficiency than HIV and may be transmitted on paraphernalia other than needles and
syringes (Van Beek et al., 1998). IDUs in Australia commonly share swabs, spoons, filters, water and
tourniquets (Crofts, Caruana, Bowden et al., 2000). The public health message of not sharing needles
and syringes may be inadequate for control of HCV and other strategies must be canvassed such as
encouraging different ways of using drugs. 
A sample of 511 ‘hidden’ drug injectors, of whom only 29% had any specialist drug treatment agency
contact, completed a questionnaire that was distributed with the ‘Fitpack’ (Lenton et al., 2000). The
study used a sample of the IDUs that are not typically seen in peer recruited and agency research. 
This is important as it may uncover trends in risk behaviour typically undetected in the large number 
of hidden injectors (Lenton et al., 2000). The questionnaire included questions on blood-borne viral
infection risk behaviour. The mean age at which respondents first injected a drug was 19 years. The
majority of the sample had injected less frequently than daily over the previous month. Overall, 40%
had shared a needle (passed it on/received it) in the previous month. Those who shared needles were
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more likely to share other equipment such as spoons, filters, water and tourniquets. Associated
characteristics included being under 26 years of age, injecting daily and sharing with a sexual partner
(59%) or a close friend (40%). In total, over half of the sample (59%) reported sharing other injecting
equipment such as spoons, filters, water and tourniquets. 
A total of 36% of the sample that reported sharing needles, cited not having enough money to buy 
a Fitpack as a reason. Almost 40% of the sample had reused their own needles. The most common
reasons for reuse were cost of equipment, frequency of injecting and access issues. This highlights 
the need for education about the risks associated with reuse of equipment.
One suggestion from respondents included the sale of sterile water and swabs within the Fitpack.
Vending machines were also suggested as an aid to alleviating difficulties with accessing drug-taking
paraphernalia, indicating the need to extend this existing element of services. 
Loxley (2000) reported that 3000 cases of HIV were avoided in Australia in 1991 due to NEPs, and
suggested that savings in treatment costs were greater than costs associated with the operations of the
programmes, a saving of 267 million Australian dollars. However, HCV transmission is being continued,
primarily through shared injecting equipment. It is recommended that NEPs expand to ensure that
IDUs always use sterile injecting paraphernalia (Loxley, 2000).
Hurley & Jolley (1997) used an ecological study design to measure the effectiveness of NEPs for the
prevention of HIV. They compared changes over time in HIV seroprevalence in IDUs worldwide for
cities with and without NEPs. The authors clearly defined NEPs, specified inclusion criteria for the 
study and described how they calculated the rate of seroprevalence for each city. The average rate 
of seroprevalence change was compared between cities in which no NEP was introduced during the
seroprevalence period and those in which an NEP had been introduced when seroprevalence among
IDUs was below 10%. Logistic regression analysis was used. A total of 81 cities with HIV seroprevalence
measurements for more than one year and information on NEP implementation were identified. Hurley
& Jolley (1997) reported that in cities with NEPs, HIV seroprevalence among IDUs decreased on
average whereas the opposite was true in cities without NEPs. They concluded that NEPs led to a
reduction in HIV incidence among IDUs. NEPs have the potential to directly decrease HIV transmission
by lowering the rate of needle sharing and indirectly through activities such as referrals to drug
treatment centres and education about ‘at risk’ behaviour (Hurley & Jolley, 1997). 
Europe
The experience of Amsterdam (Buning, 1991) suggests that harm reduction programmes facilitate 
a low level of HIV seroprevalence amongst drug users in these cities. Multicentre studies in London
(Stimson, 1996) indicated that HIV incidence amongst IDUs can be reduced by participation in harm
reduction programmes. Stimson (1996) noted that the implementation of these programmes has often
been resisted by local communities for fear of adverse effects on their business and that such areas will
be labelled as ‘drug areas’. In order to introduce such programmes into a community, effective
communication is necessary to alleviate these concerns. Further European studies are discussed
amongst others in the section below. 
Injecting Risk Behaviour 
The main aim of NEPs is to reduce risky injecting behaviour (Cox & Lawless, 2000). Wood et al. (2002)
conducted a study to identify why IDUs have difficulty accessing needles despite the availability of
NEPs. Participants were recruited from the Vancouver Injection Drug User Study (VIDUS) and included
IDUs (N=942) who returned for follow-up during a one-year period. Of these, 81% injected drugs in the
last 6 months and were included in the study. 
Participants were divided into 2 groups, those reporting difficulties accessing needles compared to
those with ease of access. Non-parametric tests were carried out to compare the two groups. Data was
stratified so that participants were divided into those who acquired most of their needles from fixed
site NEPs, exchange vans or from pharmacies. Wood et al. (2002) reported that the most common
reasons regarding difficulties accessing sterile needles included the operating hours of the NEP,
difficulty meeting the exchange van, being away from the area where needles were being exchanged,
being refused sterile needles at pharmacies and being incarcerated in the last 6 months. Frequent
cocaine injection and bingeing were also reported as being associated with difficulties accessing needles.
In the overall logistic regression model, characteristics associated with difficulty accessing sterile
needles included youth, being male, frequent injecting and living farther away from the exchange
facilities. Operational difficulties within the NEPs were associated with difficulties in accessing needles.
Being incarcerated was also associated with needle sharing, therefore the importance of considering
NEPs within the prison services must be acknowledged. Wood et al. (2002) reported that IDUs who
obtain needles exclusively from needle exchanges were half as likely to share needles than IDUs who
acquired their needles from other sources. This suggests that NEPs are an important factor in
minimising sharing of injecting paraphernalia. 
Klee, Faugier, Hayes & Morris (1991a) compared IDUs who regularly attended NEPs with those who
attended rarely or not at all. They concluded that regular use of NEPs was associated with the lending
and borrowing of equipment with others in the 6 months prior to the interview. Almost 60% of those
attending a needle-exchange lent injecting equipment to others compared to 42% of non-attenders.
The main reason reported for passing on equipment was pressure from non-attending friends. The
results also indicated that the attenders were less likely to borrow injecting equipment (36%) compared
to non-attenders (39%). 
Further analysis demonstrated that regular users in long-term treatment were less likely to pass on their
equipment (48%) compared to those who were in short term treatment (36%) or those not attending
treatment (34%). Klee et al. (1991a) suggest that the influence of NEPs is likely to be affected by many
factors including availability of equipment, age profiles of injectors and the user-friendliness of the service. 
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In another study by Klee et al. (1991b), risk behaviour among IDUs in the North West of England was
investigated. Information was collected on respondents’ sharing of injecting equipment, respondents’
sexual partners and the use of condoms. A total of 303 IDUs were interviewed at time 1 (T1). Between 
6 and 9 months later (T2), 56% of this group were interviewed using a semi-structured interview. The
emphasis at T2 was to assess changes in users’ risk behaviours. Results indicated that there were
significant reductions in sharing, mostly in the more indiscriminate use of others’ injecting equipment.
Sharing between friends showed less decline. There was no reported change in sharing between
sexual partners. Klee et al. (1991b) suggest that harm reduction messages aimed at partners should
focus on the unknowns of past and current sharing practices. These authors also note that there is a
considerable level of unprotected sexual activity by those who are sharing injecting paraphernalia.
Unprotected sexual activity is associated with the transmission of HIV, HBV and HCV. This issue needs
to be addressed within a harm reduction programme. The majority of the sample had not changed
their behaviour particularly with regard to borrowing equipment. 
In a study of 111 IDUs in Marseille, Lovell (2002) concluded that risky injecting behaviour exists despite
harm reduction strategies such as needle dispensing machines. Lovell (2002) suggests that targeting
individual-level characteristics and providing clean paraphernalia and related information may not be
sufficient to change the distribution of risk. She states that understanding the importance of other
factors such as social issues and context helps to explain why some IDUs ‘risk risk’ (Lovell, 2002). Lovell
(2002) hypothesises that risky injecting behaviour is closely tied to extreme poverty and that amongst
the disadvantaged drug injectors, a subgroup exists that lacks either the resources or the social
competency to procure drugs. This led to behaviours that included receiving ‘tastes’ of drugs from
others used syringes, and extracting heroin residue from used filters and discarded syringes. In her
study she also notes a second observation on risky injecting behaviour, which was the contradiction 
of police harassment co-existing with legal NEPs. Law enforcement officers kept track of mobile NEPs
as a means of tracing drug traffic. IDUs stopped using the van programme because of police activity
nearby. Similarly, some neighbourhoods in which IDU was high, opposed the establishment of mobile
NEPs meaning users had to leave the area to access sterile equipment. 
Keene, Stimson, Jones & Parry-Langdon (1993) conducted a study to evaluate NEPs for HIV prevention
among opiate and non-opiate IDUs in Wales. IDUs attending 8 NEPs were monitored with comparative
cross-sectional studies of non-attenders from the IDU population in 1990 and 1991. Information on 
risk behaviours was collected by questionnaire. Non-attenders were recruited through drug users,
pharmacists and drug services’ staff. All NEPs in this study offered needles, syringes, safe containers
and AIDS literature. Most offered swabs and condoms. In 1991, 17% of attenders had shared in the last
year, compared to 53% of non-attenders. Sharing in the past 4 weeks had occurred in 9% and 10% of
attenders in 1990 and 1991 respectively compared to 41% and 49% of non-attenders. Having no money
to buy clean equipment was reported as a reason for sharing paraphernalia. 
A similar proportion of both attenders and non-attenders reported cleaning their equipment before
sharing (86% and 85% respectively). This study suggests that NEPs play a role in minimising risk
behaviours regarding sharing injecting paraphernalia. 
The above literature suggests that NEPs are effective in reducing injecting risk behaviour among
regular attendees. Cox and Lawless (2000) note that the influence of such harm reduction programmes
upon sharing of paraphernalia is not straightforward. They comment that it is likely to be affected by
many extraneous factors such as availability of equipment, profile of injectors, educational strategies
and user-friendliness of the service. Wood et al. (2001) concur that several risk factors remain
independently associated with needle sharing; having difficulty getting sterile needles, needing help
injecting, reusing needles and frequent cocaine and heroin injection. Wood et al. (2001) acknowledge
that NEPs are unable to address all of these issues. 
Key Points
■ Injectors frequently report sharing needles and syringes due to difficulties in accessing them
■ Access to needles and syringes varies both nationally and internationally through contact centres,
outreach workers, vending machines, mobile vans and pharmacies 
■ Variations exist in opening hours of harm reduction services
■ The public health message of not sharing needles and syringes may be inadequate for control of
HCV and other strategies should be promoted such as encouraging other ways of using drugs
other than injecting
■ Greater emphasis on HCV transmission as part of NEPs may ensure that drug users perceive the
sharing of drug-taking paraphernalia as risky behaviour
■ Users may need education about the risks associated with reuse of equipment 
■ Harm reduction messages aimed at partners should focus on the unknowns of past and current
sharing by IDUs 
■ The research indicates that the harm reduction message of safe-injecting practices is not being
received by young injectors 
■ Research on HCV transmission associated with sharing pipes and other equipment to date is
insufficient and needs to be developed
■ Longer duration of drug use is consistently associated with acquiring HCV in IDU
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Chapter 7
Harm Reduction Programmes in Ireland
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In this chapter the development of harm reduction programmes in Ireland is considered. The nature
and extent of services available in Ireland is presented and the regional distribution spread of services
is discussed. Reference is made to the effectiveness and uptake of services and the NDS (2001) aims in
relation to harm reduction. Research on the effectiveness of Irish services is presented. 
Since 1992, the Irish Government has actively pursued a policy of harm reduction for IDUs by providing
methadone maintenance and needle exchange at both regional and local levels (Butler, 1991). The
emphasis on a pragmatic harm reduction approach has developed in line with increasing concern about
the health implications of the rise in the incidence of HIV, HBV and HCV (Northern Area Health Board,
2001). In Ireland in the early 1980s, the sharing of non-sterile needles and syringes led to IDUs being
identified as a high-risk group for the development of HIV (Butler, 1991). Of the total number of HIV
positive cases reported to the end of June 2002, 37% were IDUs (NDSC 2002). The EMCDDA (2002)
annual report estimates that about 5.7% of the Irish population between the ages of 15-64 engage in
problem drug use. Problem drug use is defined as injecting drug use or long/duration use of opiates,
cocaine and/or amphetamines (EMCDDA 2002). The highest estimates are reported for Italy,
Luxemburg, Portugal and the United Kingdom, while estimates are lowest in Austria, Germany and the
Netherlands. According to the NACD (2003) problem opiate use in Ireland is estimated at 5.6%. in 2001.
The number of opiate users in the Eastern Regional Health Authority (ERHA) catchment area in receipt
of methadone rose from 150 in 1992 to 3,000 by the end of 1997 (Fitzgerald, Barry, O’Sullivan &
Thornton, 2001) and to 6, 672 at the end of January 2003.
The development of drug services has seen improvements in the type and quantity of data being
collected on drug use and associated treatment. One of the advances in this area is the creation of a
central list quantifying the number of people in treatment. Current figures on the Central Treatment
List (ERHA 2003) indicate that there are now 6,883 at December 2003 (National Drug Treatment List
2003) accessing treatment from a range of services. This information is a useful tool both in monitoring
the uptake of current services and in planning future developments. 
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Table 1: Central Treatment List (ERHA 2003) – all people registered for treatment 
Breakdown of Patients Dec 2003
ERHA Clinics 3,543
National Clinics 123
Trinity Court 501
Prisons 402
General Practitioners within ERHA area 2,160
General Practitioners outside ERHA area 154
Total 6,883
Area Breakdown of Participating Pharmacies
Pharmacies within ERHA area 187
Pharmacies outside ERHA area 108
Total 295
Area Breakdown of Participating General Practitioners
The No. of GPs participating within the ERHA area 171
The No. of GPs participating outside the ERHA area 34
Total 205
Action 22 of the current Health Strategy, Quality and Fairness – A health system for you (Department 
of Health and Children 2001), refers to initiatives to improve the health and well being of drug users
through the implementation of the NDS by 2008. The National Drug Strategy contains 100 key actions
to be implemented by the various stakeholders. The salient points in reference to this review are
presented below.
The National Drug Strategy (2001-2008) 
The overall aims of the NDS (2001) are based on: 
■ The reduction of risk behaviour associated with drug misuse 
■ The reduction of the harm that drug misuse causes to individuals, families and communities
■ Enabling people with drug misuse problems to access treatment and other supports in order 
to re-integrate into society. 
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It is clear that the NDS is supportive of harm reduction with respect to the drug users, their families
and communities. While harm reduction can be defined as a concept based on the prevention and
reduction of negative health consequences associated with drug misuse, the NDS lacks a clear
definition of harm reduction. The inclusion of an ultimate aim of a drug-free life in reference to harm
reduction is not consistent with a harm reduction message. 
Action 62 of the NDS proposes a review of the existing network of needle exchange facilities, with a
view to ensuring access for all drug users to sterile injecting equipment. Action 63 is a commitment to
set up a pilot Community Pharmacy NEP in the ERHA, and action 69 deals with the development and
implementation of collection and safe disposal facilities for injecting equipment.
A working committee comprising of various representatives of the three ERHA area health boards was
established in December 2002 to oversee the implementation of these actions. 
Current Irish Services
The Northern Area Health Board (NAHB), the South Western Area Health Board (SWAHB) and the East
Coast Area Health Board (ECAHB) offer harm reduction programmes including needle exchange from
fixed sites, mobile units and outreach work. Outreach workers frequently practise ‘backpacking’ – a
process whereby staff, in the absence of a local clinic or mobile unit, carry supplies of drug-taking
paraphernalia for distribution to known drug misusers. Additional services operate from the Merchants
Quay Project, and other sites in the greater Dublin area run in partnership with the ERHA and a number
of voluntary organisations. Some of these services are on a sessional basis or simply a fixed time once
per week. Outside the ERHA, harm reduction services are less developed and have not yet produced
statistics on attendance figures. The range of harm reduction services varies from site to site, which is
described in chapter 8. Harm reduction services report initiatives including free needle exchange,
alcohol wipes, sterile water, citric acid filters, spoons, condoms and the provision of methadone. 
The uptake of harm reduction by IDUs can be monitored through attendance rates at NEPs, although
attendance figures do not indicate the quality of services. The average weekly numbers attending
needle exchanges in the ERHA and the Merchants Quay Project are presented in Table 2 below
(Working Group on Needle Exchange, 2003). From this it is evident that the Merchants Quay Project
has a greater number of attenders in comparison to NAHB, SWAHB and ECAHB services.
Table 2: The Estimated Weekly Numbers Attending NEPs
NAHB 100
SWAHB 50-70
ECAHB 80-110
Merchants Quay 400-500 of whom 20 
are new attendees per week
NAHB Harm Reduction Programmes 
In the 2001 Provider Plan, the NAHB stated that harm reduction measures would continue to be a focal
point for their service provision. Their strategy aims to concentrate on making risk practices as safe as
possible as well as trying to change long-standing risk behaviour. To date these initiatives include the
recruitment of a hepatitis C co-ordinator nurse to maximise links between acute hospitals and drug
services and to ensure integrated service delivery for people with HCV who use drugs. 
In 2002, harm reduction programmes available in the NAHB included methadone treatments, NEPs,
screening for HIV, HCV, HBV and sexually-transmitted diseases (STDs), a mobile clinic that provides
both a low-dose methadone programme and a specialist programme for women in prostitution. 
There were 2,341 reported drug users in treatment within the NAHB by the end of 2001 (NAHB, 2002).
Harm Reduction in Detention Centres and Prisons
The NAHB (2001) stated that one of their targets is that prisoners be appropriately identified as having
a drug-addiction problem and receive necessary treatment. It is also suggested that their treatment is
followed up on committal and in the community upon release. In this way, the addiction services would
be able to provide continuity of care both within and outside the prison. There is inequity in the range
of services available to IDUs detained within the prison system compared to those available within the
community. 
South Western Area Health Board Harm Reduction Programmes 
In the 2002 Provider Agreement, the SWAHB stated that it aimed to provide high quality, accessible
and responsive addiction services. Within the SWAHB, services provided include NEPs, provision of
harm reduction information and advice regarding safer sex practices. In addition to the above services,
backpacking is also available. They also provide methadone treatment and maintenance. 
East Coast Area Health Board Harm Reduction Programmes 
In the 2002 Provider Agreement, the ECAHB stated that its addiction service aims to assist individuals,
families and communities affected by substance abuse. The ultimate goal of the service is to help the
individual abusing substances to achieve and maintain a drug-free lifestyle. The Board recognises that
this goal is not feasible for everybody and a variety of interventions are provided to enable the
individual abusing substances to achieve as normal a lifestyle as possible. NEPs operate from several
locations along with the provision of harm reduction information, safer injecting information and safer
sex information. A mobile bus service and a backpacking service are also provided within this area
Board. They also provide methadone treatment and maintenance.
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Sharing of Drug Taking Paraphernalia in Ireland
In a cross-sectional study of 246 IDUs attending addiction services in Dublin, Smyth, Barry & Keenan
(2001) found that 70% of participants reported syringe borrowing. Using multivariate analysis, they
identified seven characteristics associated with this risk behaviour. IDUs with long injecting histories
who injected less frequently were more likely to borrow. The authors suggested that these ‘established,
less frequent injectors’ inject more opportunistically and may become complacent over time about
sharing with other IDUs. Injection of more than one substance and having more intimate social
relationships with other IDUs were also significantly associated with syringe borrowing. This finding
supports the international literature in relation to this point (Cassin, Geoghan & Cox, 1998, Gossop 
et al., 1997, Stark, Muller, Wirth et al., 1995, Saxon, Calsyn & Jackson, 1994). 
Smyth et al. (2001) reported that almost one quarter of the IDUs who borrowed syringes did so
frequently (i.e., more often than one-in-every-10 injections). Only 13% of the sample had completely
avoided borrowing spoons or filters from other IDUs. ‘Halving’ was frequently practised. According to
Smyth et al. (2001), these findings contribute towards explaining the early acquisition of HCV by IDUs in
Dublin. Overall, studies on the frequency of sharing equipment highlight that this is an issue that needs
to be vigorously addressed in harm reduction services. 
Smyth et al. (2001) identified that syringe borrowing persists amongst IDUs in Dublin despite the
existence of harm reduction programmes and recommends that interventions should include exploring
the unique attitudes and beliefs regarding unsafe injecting with each individual. The findings of Dolan
et al. (2003), Smyth et al. (2001) and Wood et al. (2001), all suggest that NEPs on their own are not
sufficient to eliminate the risks associated with sharing drug-taking paraphernalia. 
Prevalence of HIV, HBV and HCV in Irish Drug Misusers
Consistent approaches to screening for infectious diseases support the development of a profile of
prevalence and incidence rates of blood-borne infectious diseases among IDUs. This information is
valuable in the ongoing development and evaluation of harm reduction services. The National Disease
Surveillance Centre (NDSC) compiles and publishes statistics and information on the transmission 
rates of blood-borne infections in Ireland. This information is broken down to show trends in the most
common exposure categories. Currently IDUs account for 37% (1048 cases) of those diagnosed with
HIV in Ireland (NDSC 2002). Analysis of the figures published by the NDSC show that the number of
cases of IDUs with HIV infection steadily increased between 1998 and 2000. During the following year
2001-2002, a reduction of almost 50% in this category is recorded, (see table 3). This trend to a
lowering rate of infection requires ongoing analysis to ascertain if a link can be found between
expansion of harm reduction services and reduction in the rates of transmission of HIV. It must also 
be emphasised that newly-diagnosed infections do not represent HIV incidence, as diagnosis may 
be several years after infection is acquired (Cronin, & O’ Donnell, 2002).
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Table 3
(National Disease Surveillance Centre 2002)
Trends in HIV prevalence over time are important for policy and evaluation purposes. In recent years,
increases in HIV transmission have occurred in regions or cities in Europe such as Ireland, Italy, the
Netherlands, Portugal and Finland (EMCDDA 2002). The EMCDDA (2002) record a prevalence rate of
3.5-8.7% of HIV infection between 1996 and 2001 in Ireland among IDUs. Highest rates are recorded 
for Spain of 33.5% and lowest for Sweden at 2.6%. However, these figures need to be interpreted with
caution as source types may differ, for example prevalence rates in Spain are taken from IDUs in
treatment and may not represent IDUs not in treatment. 
In Ireland, information on viral hepatitis rates is reported under the headings viral hepatitis type A, viral
hepatitis type B and viral hepatitis unspecified. The NDSC (2001) records a total of 90 newly-reported
cases of viral hepatitis unspecified in 2001. These figures are classified by age category, with 12 people
aged 20-24 years, 40 aged 25-34 years and 11 respectively in the 35-44 and 45-54 age groups reported
as becoming infected in 2001. The remaining age categories recorded infection rates of fewer than 5
people in each range. This predominance of infection with HCV in the age group 20-54 is consistent
with the age group most associated with drug misuse. HCV prevalence is extremely high in all
countries and settings in Europe, with infection rates of between 40 and 90% among different sub
groups of IDUs (EMCDDA 2002). The EMCDDA (2002) reports a prevalence rate of 72-73% of HCV
infection among IDUs between 1996-2001. 
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In Ireland there has been no routine data collection on HCV prevalence rates (Dillon & O’Brien, 2001).
However, there have been a small number of studies carried out on various samples of drug users
revealing a high prevalence of HCV among Irish IDUs. Smyth, Keenan, Dorman & O’ Connor (1995)
conducted the first Irish study of HCV infection among IDUs. They identified a sample of 272 IDUs in
treatment and reported a HCV prevalence rate of 84%. Among those who had been injecting for
between 6 months and 2 years, the reported prevalence of HCV was 70%. Among those with an
injecting history of greater than 2 years, a higher prevalence rate of 95% was reported. A study by
Crofts, Stewart, Hearne et al. (1995) supports the findings that longer duration of drug use is
consistently associated with HCV in IDUs. Smyth et al. (1995) reported a significant gender difference 
in relation to infection: of the 194 males, 80% tested positive compared to a 94% positive rate among
the group of 78 females. 
Many localities outside Ireland report HCV prevalence above 85% among active users (Pollack, 2001). 
Other Irish studies have reported HCV prevalence rates of between 52% (Smyth, Keenan & O’Connor,
1999) and 79% (Fitzgerald, Barry, O’Sullivan & Thornton, 2001). Smyth, Keenan & O’Connor (1998)
reported that of 733 consecutive new attenders at a treatment centre between September 1992 and
September 1997, 62% were identified as HCV positive. In the following year, in a sample of 353
consecutive new attenders, Smyth et al. (1999) identified a comparatively lower prevalence rate of 52%. 
Effectiveness of Irish Harm Reduction Strategies
The introduction of NEPs represented the first Irish public health policy explicitly advocating harm
reduction interventions aimed at reducing HIV risk behaviour, without necessarily reducing illicit drug
use (Cox, Cassin, Lawless & Geoghegan, 2000). International research demonstrates that NEPs are
useful in the delivery of an effective service, improving access to sterile injecting equipment and
reducing levels of injecting risk behaviour. These programmes may be a useful referral source for 
IDUs and may operate as a point of entry into additional treatment services.
Cox et al. (2000) conducted the first Irish study examining the effectiveness of NEPs as a harm
reduction strategy over an 18-month period. A total of 370 IDUs completed questionnaires on 
two occasions, time 1 (T1) and follow-up data at time 2 (T2), three months later. Two structured
questionnaires were administered at T1 and T2 by trained staff. In line with the trends in the literature,
the majority of the group was male (79%) with a mean age of 23 years. Their average injecting career
was 2.6 years and almost half of the sample had served a term in prison. A total of 5% of the sample
reported being HBV and 16% being HCV positive. 
The results support the position that NEPs play an important role in significantly reducing the numbers
reporting both the use of heroin as a primary drug at T1 (94%) and its frequency of use at follow up
(87%). A total of 67% of those who reported injecting their primary drug four or more times a day at 
T1 had reduced that to once a day or less by the follow-up period. At follow up, respondents were
significantly more likely to report hygienic and safer injecting practices. There was a 44% increase at 
T2 in respondents who reported cleaning their injecting site. 
At T1, 24% of the sample reported recent borrowing and 15% recent lending of needles and syringes.
There were significant changes in both behaviours across T1 and T2. Over 70% of those who reported
borrowing at T1 had ceased this behaviour at T2. Respondents reported a decrease in lending used
needles and syringes at T2. 
Although there were significant reductions in reported borrowing and lending of used needles and
syringes, there were no significant changes reported in sharing injecting paraphernalia or in condom
usage. Additionally, between T1 and T2, 41% of respondents commenced sharing injecting
paraphernalia such as spoons and filters. This finding is of particular concern within an Irish context, 
as sharing injecting paraphernalia is reported as a means of facilitating the spread of HCV. Cox et al.
(2000) suggest that greater emphasis be placed on the provision of information regarding HCV
transmission. 
Cox et al. (2000) recommend that service development should include NEPs at local levels, including
strategies such as strategically-placed vending machines, mobile exchanges and pharmacy
involvement in distribution. Increased availability of paraphernalia cannot eliminate all sharing
behaviour as environmental, economic, cultural and social factors can impact on sharing injecting
paraphernalia (Klee et al., 1991a). Cox et al. (2000) support the contention that NEPs can be an
effective public health initiative in reducing sharing of drug-taking paraphernalia. 
Smyth et al. (1999) hypothesised that there would be a lower prevalence of HCV in those who started
injecting between 1991 and 1993 as a result of the increase in harm reduction programmes in Dublin.
Consecutive attendees at a drug service were tested for anti-HCV between 1993 and 1996. Results
indicated that those who started injecting between 1991 and 1993 and those with injecting histories
less than 13 months were at a reduced risk for HCV. This study supports the effectiveness of service
expansion with the reduction of unsafe injecting practices. As controls for other factors are excluded,
results need to be interpreted carefully.
In another cross-sectional study, Smyth et al. (2001) indicated that in the 6 months prior to the study,
87% of respondents borrowed spoons and filters from other IDUs on more than one-in-every-10
injections. A total of 70% borrowed syringes from others. The high level of recent unsafe injecting by
this young population (median age of 22 years) helps to explain the early acquisition of HCV by IDUs 
in Dublin. The rate of reported recent sharing was greater than that found in a previous Irish study
(Dorman, Keenan, Schuttler, et al., 1997). Smyth et al.’s (2001) study suggests that the messages about
risk behaviour are not being transmitted in a timely manner to young IDUs. 
The results of Smyth et al. (2001) do not support a hypothesis that unsafe injecting has reduced in
response to an expanded harm reduction programme. Smyth et al. (2001) suggest that this may be 
due in part to the population being younger than that in other studies. The data suggests that those
who inject benzodiazepines as well as heroin appear to be particularly at risk. According to the Report
of the Benzodiazepine Committee (Department of Health and Children, 2002), heroin was most
commonly reported as the main drug of abuse in 1997 and in 1998. This suggests that harm reduction
programmes need to be aware of polydrug use and incorporate relevant interventions such as
comprehensive assessment and treatment of all drug-taking behaviours into their programmes.
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Dorman et al. (1997) measured HIV prevalence and risk behaviour in 185 Irish IDUs. They found that
56% shared and 62% lent injecting equipment in the previous six months. The vast majority of those
who shared (94%) always cleaned needles before use, but only half of this group cleaned needles in 
an efficient manner. This finding suggests that over half of the sample engaged in risky injecting
behaviours and adds to the body of literature that reports sharing injecting equipment as a risk
behaviour engaged in by Irish IDUs. 
Cassin et al. (1998) compared injecting and sexual risk behaviour of young injectors with those greater
than 25 years of age. All respondents (N=770) presented for the first time at the Merchants Quay
Project between May 1997 and February 1998. Data were collected by means of a structured
questionnaire at baseline and 3 months later. 
The results indicated that young injectors are more likely to report recently borrowing and lending 
of used needles and syringes and other drug-using paraphernalia. This finding is also supported by
Mullen & Barry (1999) who reported that sharing was more prevalent in the younger age group,
decreasing significantly in those over 30 years of age. This suggests that young injectors are not
responding to harm reduction messages. In Cassin et al.’s study (1998), young injectors were more
likely female, had started injecting earlier than their male peers and were using heroin. Both groups
were polydrug users. Young injectors were also less aware of their HCV status than the older group and
were less likely to report having had a HIV test or been vaccinated against HBV. 
Cassin et al. (1998) noted that the high levels of risk behaviour in young injectors may be due to the
lack of emphasis on harm reduction strategies in the years prior to the study. Sendi et al.’s (2003) study
found that individuals with a longer history of injecting drug use and of a younger age were more likely
to withdraw from an intravenous opiate-maintenance programme. This finding supports the proposal
that younger users need particular considerations. The results suggest that harm reduction messages
regarding minimising risks associated with sharing injecting paraphernalia need to be appropriately
and adequately targeted towards young users. 
Key Points
■ International trends in the concepts and methods associated with harm reduction have been
established during the past two decades
■ The Irish Government has supported harm reduction strategies since 1992
■ Three actions for harm reduction are identified in the National Drug Strategy (2001-2008)
■ Harm reduction programmes in Ireland are mainly concentrated in the Eastern region
■ Harm reduction programmes operate in a range of settings, fixed sites, mobile units and through
outreach work
■ Ongoing surveillance of the transmission rate of blood-borne infection amongst IDUs may provide
useful information about the outcome of harm reduction programmes 
Chapter 8
Self Reporting on Harm Reduction in Irish
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There is a dearth of published literature on how Irish harm reduction services conduct their work.
Statistics are available within some services on gender, age, and uptake of screening for infectious
disease and the numbers of IDUs who attend services. However, these statistics do not indicate what
formal and informal links harm reduction services have with other agencies, how services operate with
regard to health care advice, or whether they have developed appropriate policies and procedures.
There is no published information available profiling the group of staff delivering these services,
indicating what access they have to ongoing education and training or recording their concerns and
difficulties in operating harm reduction services. The ERHA have commenced work on profiling this
group of staff. The authors believed it would be beneficial to gather information from primary sources
about the day-to-day work conducted in Irish harm reduction services. 
Questionnaire Design and Research Methodology
In order to amass the required information, a purposeful sample of services was chosen. The most
appropriate method of gathering this information was to conduct a series of telephone interviews 
with staff working in addiction services. Key informants were identified through the Regional Drug 
Co-ordinators and Area Operations Managers within the Health Boards. 
The literature review informed the authors of the questions to address to service providers. A
questionnaire was designed (Appendix A) and a pilot study conducted to test its suitability for gathering
the required information. Following piloting, the questionnaire was reviewed and modified to the needs
of the project. The questionnaire included a total of sixteen closed and open questions that enabled the
authors to gather data including informants’ experience and beliefs about service delivery. 
Each interview took 30 minutes to administer. Three members of the project team conducted
interviews. Initially telephone contact was made with the identified informant in which they were given
information about the review and the purpose and duration of the telephone interview. A suitable time
was agreed to conduct the interview. In order to ensure the anonymity of respondents and the service
in which they operated, they were informed that material they shared would be included as part of the
overall report but not linked directly to the service they provide. To account for the concentration of
services on the east coast, the information presented outlines, similarities and differences between
information received from ERHA respondents and respondents from other Health Boards. Following
the interviews, written transcripts were collated and this generated the information presented below. 
To gain a national spread of responses, informants were contacted in each Health Board Area.
Representatives from all of the Health Board Areas were approached. All of the services contacted
were supportive and actively participated in the study. A total of 16 respondents were contacted. 
Of the 16 contacted, 13 reported that their work included harm reduction with drug users who used
paraphernalia to administer drugs. Engaging with this identified group of drug users was an essential
inclusion criterion. The interviews were discontinued in 3 cases when the harm reduction worker
responded that drug users who shared drug-taking paraphernalia were not availing of services in 
the area. The authors are aware of the limitations inherent in a small sample group. However, the
information generated concurred with material highlighted in the literature review. This limitation 
must be taken into account when generalising about national harm reduction services. 
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Scope and Limitations of the Study
The sample size in this study is small for a variety of reasons. These include the scope, terms of
reference and duration of the study. A purposeful sample was therefore chosen upon considering 
these factors. Despite the small sample, a number of interesting points were generated which reflected
material in the literature review, adding support to their validity. However, it is difficult to generalise
about national services based on these findings as other potential useful informants may have been
excluded.
All of the respondents acknowledged that their work included harm reduction, including the three 
in which interviews were discontinued as described above. One respondent outside of the ERHA
commented that there is no official harm reduction programme in place in that service, however 
some staff engage in harm reduction activities.
Addictions Treated 
Services outside the ERHA mainly treated alcohol misuse and illegal drugs such as cannabis and
ecstasy. A number of these services (N=3) reported treating heroin users and one respondent
mentioned that they offer services to a small number of IDUs. 
In contrast, all respondents within the ERHA reported treating IDUs. All respondents working within 
the ERHA commented that they treat opiate users including three reports of treating cocaine use. A
minority of respondents reported treating benzodiazepine addiction. Clearly, service provision within
the ERHA is more focussed on opiate users than that provided within other Health Board areas.
Harm Reduction Programmes Offered By Irish Services
Outside of the ERHA, harm reduction programmes mainly consisted of methadone provision. 
In contrast, harm reduction programmes within the ERHA were broader in scope, providing free 
needle exchange alongside methadone maintenance.
One-for-one needle exchange is provided although one respondent made a comment that more
needles may be provided to well-known clients. Alcohol wipes, sterile water and citric acid are
provided by all services within the ERHA. Filters are provided by half of the ERHA respondents with 
the majority also providing spoons. No respondent reported providing pipes. 
In reference to the promotion of safe practices, the majority of respondents within the ERHA promote
safety in sharing other injecting paraphernalia. The responses within the ERHA sample reflect
recommendations in the literature around minimising the risks associated with sharing injecting
equipment. Providing users with the means to change risk behaviour is important. Many of the services
represented here provide education and equipment to promote safety in sharing injecting paraphernalia.
Reported Purpose of Harm Reduction Programmes
Similar responses were provided from service providers nationally regarding the main purpose of their
harm reduction programmes. The majority reported the main purpose as reducing harm to drug users.
Other comments included reducing the transmission of infectious diseases. Two ERHA respondents
reported linking drug users into their or other services for support. The provision of education in
relation to safe injecting practices was reported by half of the ERHA respondents. 
Reported Targets of Harm Reduction Programmes 
In addition to drug users and IDUs being targeted for service provision, some respondents commented
that women with children are a priority target. All respondents mentioned that the homeless and those
with HIV are priority groups for services. Those with mental health issues, polydrug users and those
linked to methadone programmes were also mentioned.
The vast majority of respondents (all ERHA and some outside the ERHA) reported that specific issues
such as HIV, HCV and HBV are addressed. Sexual health, lifestyle issues and infection prevention in
relation to needle sites were included within the responses. 
Harm Reduction Strategies and the Specific Issues They Address
All respondents within the ERHA reported providing information on choosing, rotating and caring for
injection sites. Only a minority outside the ERHA reported the same. The majority of those working
within the ERHA, unlike those working elsewhere, commented that they discuss issues with IDUs
around specific injecting techniques. Respondents nationally reported differences in the manner of
recording what health care advice is being delivered.
Similar themes emerged across the sample, which included: offering advice and education around safe
practice, overdosing and general health issues. Within the ERHA, half of the respondents reported
providing education and advice around safer smoking and polydrug use. A number of respondents in
both groups reported providing condoms. No respondent reported delivering advice about alternative
methods of drug administration, which contradicts recommendations highlighted in the literature. 
Access to Services
In the main, services were described as opening during office hours. Three people within the ERHA
reported some evening opening hours. Weekend opening hours were only reported by two services
outside the ERHA. 
Limited opening hours for many contribute to the sharing of injecting paraphernalia. The literature
indicates that users share paraphernalia despite the associated risks when clean equipment is
inaccessible. Countries including Germany and Switzerland use vending machines, which dispense
needles to minimise the problems associated with limited opening hours. The low reported regional
spread of IDU should not encourage complacency about the availability of needle exchange. The
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literature indicated that particular groups such as prisoners and young people tend to be opportunistic
about IDU and therefore it is imperative that access to appropriate paraphernalia is improved. Where 
it is not viable for Health Boards to provide exchange services or extend opening hours, initiatives such
as vending machines and dispensing through community pharmacies should be considered. 
Services nationally reported that drug users could access services without a prior appointment. Some
services also reported a referral system. It is important to note that even though access is freely
encouraged, all services reported high levels of activity, indicating that the amount of individual time
that can be spent with each attendee is limited. This coupled with limited opening hours mitigates
against ease of access. 
Advertising Services 
Various methods are employed to advertise harm reduction services. Word of mouth was the most
frequent means employed within the ERHA. Other popular methods reported elsewhere in the country
included health centres, health board directories or brochures and leaflets. Early access to services may
be important in minimising risks, therefore consideration should be given to marketing services to
ensure new users are accessed promptly. 
Education and Training in Harm Reduction
Variations existed in the level and frequency of training in harm reduction. Distinctions were not made
between formal and informal training. A number of ERHA respondents referred to ongoing education
in the form of team meetings, group discussions and consultations with colleagues. Respondents
clarified that this had occurred within the last 6 months. In contrast, outside ERHA, training was
reported to have occurred at various times between six months and five years ago, with three
respondents reporting training greater than five years ago. The majority of respondents outside 
ERHA completed addiction studies training. 
A wide range of health professionals including doctors, nurses, counsellors and outreach workers were
identified as delivering harm reduction services. Considering the profile of staff engaged in harm
reduction and the variation in levels of ongoing training, service planners and managers will need to
ensure that attending formal educational and skills training of an interdisciplinary nature is a vital
component of the harm reduction workers remit. 
Links with Other Agencies
Across all Health Boards respondents stated that they have links with GPs, mental health agencies,
hospitals, pharmacies, probation officers and voluntary organisations. Some respondents reported links
with social workers. Differences emerged in the reporting of links with self-help groups within ERHA
and the other regions. ERHA respondents reported formal links with these services whereas informal
links were reported elsewhere. Additional services were linked into by ERHA workers including the
drug court, prisons, police and Citizens’ Advice Bureaus. Communication systems to develop and
maintain links and interagency collaboration are recommended. 
The Influence of Policies on Practice
Differences in responses emerged across respondents. Within the ERHA, the majority of respondents
were positive regarding the translation of operational policies into practice. This contrasts with only
two respondents commenting similarly outside of the ERHA. Policies were seen as important in guiding
staff decisions and actions and providing protection to both staff and clients. 
The development of protocols especially around under-age users and new policies remain a challenge
for those outside the ERHA. This finding was echoed by those within the ERHA with half of the ERHA
sample reporting that current policies are challenging. Balancing confidentiality and informing parents
of under-age users was reported as a challenge to service provision. 
There was unanimous agreement across all respondents that service provision departs from service
policy. Within the ERHA, the majority of respondents commented that it is necessary to ‘bend the
rules’ while providing a service. Examples of this included helping people to get treatment although
they may not be resident in the area and providing extra needles to clients. Outside of the ERHA, it
was reported that one service ‘unofficially’ provides needles, syringes, and condoms. 
Further Development of Services
ERHA respondents suggested that resources including the type of programme and opening hours
need improvement. Other suggestions included more diverse treatment models such as respite
houses, methadone withdrawal, extended mobile services and outreach work and greater inter-agency
collaboration. Similarly, respondents outside the ERHA called for an increase in resources including the
reduction of waiting lists and the inclusion of more community-focussed outreach services, e.g. to meet
the needs of homeless people. 
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Within the ERHA, half of the respondents expressed the desire that their practice should be
continuously updated to reflect current users’ needs and trends such as the perceived increase in use
of crack cocaine. Some respondents outside the ERHA suggested that there should be clear structures
and operational policies supporting NEPs. Community pharmacies and on-site dispensing of
methadone were also suggested.
Increase in resources, expansion of services, the development and implementation of relevant up-to-
date policies were among the key suggestions made by respondents. These ideas reflect themes
found in the current literature.
Legal Concerns Surrounding Harm Reduction Programmes
The main legal issue of concern to respondents was working with under-age users (i.e. under 18 years
of age) around issues of consent, confidentiality and methadone provision. 
A minority of respondents commented that they may be aware of users dealing. Sometimes this
information is not shared outside the service. One report of ‘works’ provided by the programme being
confiscated by An Garda Síochána suggests the need for improved inter-agency communication. 
Key Points
■ Differences exist between services in the range of drug-taking paraphernalia and the extent 
of health care advice offered to drug users. Advice to users which includes information about
alternative methods of administration is not given by any of the health boards
■ Access to services could be improved by extending opening hours, marketing and the introduction
of alternative services such as vending machines and community pharmacies. These were suggested
by respondents
■ Ongoing professional development will guide best practice
■ Communication systems and inter-agency collaboration present a challenge to harm reduction workers
■ Standardisation of reporting systems and record keeping along with policies and procedural
reviews were issues of concern to harm reduction workers 
■ Extensive research is required on the national spread, activities and the quality of service provision
in Irish harm reduction services
Chapter 9
Harm Reduction and Marginalised Groups 
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Within the drug-using population, groups such as the Homeless, Travellers, Women and Prisoners
experience issues particular to their unique needs. In this chapter the reader is presented with
information on harm reduction and marginalised groups in Irish society. Particular reference is made 
to the Homeless and Women. Much national and international research has been conducted in relation
to drug-using populations in prisons and is also presented in this chapter. 
Homeless Population
The profile of the homeless has changed significantly during the past decade. The number of
homeless people in Irish society appears to be steadily increasing. Greater numbers of people are 
now homeless; the population is younger and includes more females and families (O’ Gorman, 2002).
In 1990 five homeless households were placed in Bed and Breakfast accommodation. By 1999, this 
had risen to 1,202 households, which consisted of 2,780 people 1,518 adults and 1,262 children,
(Houghton and Hickey, 2000). 
While the correlation between drug misuse and homelessness has been noted in a number of research
studies, there is little specific evidence as to the extent of drug misuse amongst the homeless
population in Ireland (O’ Gorman, 2002). Holohan (1997) studied 502 homeless people in Dublin aged
over 18, 42% of this sample was under 35, 85% were male and 15% were female. The study found that
substance/alcohol abuse was the most frequently-cited cause of homelessness (24%). Lifetime
prevalence of illicit drug use was found in 27% of the sample.
The Merchants Quay Project, reporting on the numbers of homeless people availing of treatment,
found an increased risk in drug-taking practices within this population (Cox & Lawless, 1999). A total 
of 49% reported sharing needles and 92% of those sleeping rough inject in public places. 
Feeney et al. (2000) studied 171 homeless men dwelling in Dublin. More than half of the study group
were between 35-54 years and were found to be alcohol dependent. However, high levels of illicit 
drug use were also found, with 55% reporting having used drugs. In the younger age group 80% of 
the 18 – 34 year olds, in comparison to 12% of the 55-plus age group, reported ever having used illicit
drugs. This figure is consistent with findings elsewhere that youth is a factor in drug use. Of the group
who used illicit drugs in their lifetime, 20% reported ever using cocaine and 18% had ever used heroin.
Approximately half were dependent drug users, defined as using every day for two weeks or more in
the past 12 months. Almost two thirds of the respondents who reported ever using heroin were
dependent users. The sharing of needles was a factor with this group. Feeney et al. (2000) found that 
of the 12% of homeless men who reported injecting drugs, 67% (N=14) said they had shared needles.
This is consistent with Cox and Lawless’ (1999) findings on sharing.
A second study from the same period focuses on homeless families in emergency Bed and Breakfast
accommodation. Houghton and Hickey (2000) found drug addiction to be the principle factor in
becoming homeless in 16% of households from a total of 1,202 households who had become
homeless. Drug addiction was cited as a contributing factor in becoming homeless by another 11% 
of the households. In tandem with the studies above, (Cox & Lawless, 1999 and Feeney et al., 2000),
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being younger was significantly associated with homelessness and drug use. Over 38% (n=391) of 
18-25 year olds and 26% of 26-40 year olds cited drug addiction and drug-related problems as the
primary reason for their homelessness. 
Condon (2001) studied the health and dental needs of 234 homeless people in Dublin. A total of 38%
of this sample reported having ever taken illicit drugs. Almost one quarter, 24%, reported to injecting
drugs, 58% of which said they shared needles. In this study 1% of the sample reported having HIV 
and 7% (N=14) reported being HCV positive. Screening was offered to participants and 189 of the
participants were screened for HCV of which 18% (n=35) tested positive for HCV. Screening positive 
for HCV is associated with the sharing of paraphernalia for drug use. 
As noted above the profile of the homeless is changing. The number of homeless women has been
steadily increasing. Smith et al. (2001) studied the health status of 100 homeless women and their
children in Dublin. Of the 100 women interviewed, 11% specified addiction problems as the reason 
for becoming homeless. Almost 45% of respondents were classified as dependent on opiates, defined
as using every day for two weeks or more in the previous 12 months. All, bar one, reported being
involved in a treatment programme. Heroin was used by 47% of the women in their lifetime, 33%
(N=13) of those who reported ever injecting had shared drug-taking paraphernalia. A quarter of this
group reported that they were HCV positive and 2% were HIV positive. Almost 100% were involved in 
a treatment programme indicating that homeless women are able to gain access to services. However,
both Smith et al. (2001) and Condon (2001) found that sharing of equipment, and prevalence of HCV in
the populations studied, suggests that the range of services for this group may need to be extended. 
Greater numbers of people are now homeless, figures for 2000 were up 60% in the rough sleeping
count (O’ Gorman, 2002). The research evidence suggests a practice of injecting risk behaviour in the
homeless population. However, the research indicates that access to services alone does not prevent
the sharing of drug-taking paraphernalia and the transmission of HCV. Indications from the research
also point to the young homeless as being more likely to use illicit drugs and to practise sharing 
drug-taking paraphernalia. More research is required in this area to determine innovative strategies 
for earlier interventions with the homeless. Consideration also needs to be given to the development
of appropriate facilities for homeless drug users where access to primary health care can be ensured.
People Involved in Prostitution
There is a lack of published research on drug use and prostitution in Ireland. In the only available 
study of drug using women in prostitution (The Women’s Health Project, 1999), over 84% of the sample
reported injecting heroin in the month prior to the study. This group of women are at an increased risk
from both drug use and engaging with multiple sexual partners. It is paramount that they have access
to appropriate harm reduction services. 
Traveller Community
According to the NDS (2001) there is no evidence to suggest that illicit drug use among the Traveller
Community is a major issue. However, the NDS (2001) includes Travellers amongst the at-risk groups.
At the time of writing this report there was insufficient empirical information to fully assess implications
for harm reduction. In May 2003 the NACD, together with Traveller organisations, initiated a nationwide
research project amongst Traveller communities to establish the drug issues and challenges facing this
vulnerable community. 
Prison Services
Relative to the general population, prisoners have high lifetime levels of injecting (Hunt et al., 2003).
Injecting drug users are more likely to share injecting equipment while in prison than when they are 
in the community (Dillon, 2001). The limited availability of drugs within the prison setting creates an
environment in which injecting is considered the only acceptable route of administration (Dillon, 2001).
Dillon’s (2001) study also highlighted that injecting equipment was more difficult to come by in prison
and this was a factor in sharing. Since 1992, NEPs within prisons have been increasingly developed in
some European countries. Evaluations of these prison NEPs show a reduction in sharing rates and in
the acquisition of HIV, HBV and HCV (Dolan et al., 2003). Switzerland, Germany and Spain now have
NEPs available in their prisons. 
Needle Sharing in German Prisons
Muller, Stark, Guggenmoos-Holzmann et al. (1995) conducted a study of 612 IDUs in Berlin to examine
imprisonment as a risk factor for HIV infection. A total of 418 IDUs had a history of imprisonment of
which 202 continued to inject while in prison. Interestingly, 152 IDUs started sharing needles while
detained. This finding highlights the risk associated with this population. Muller et al. (1995) reported
that needle sharing in prison is the most important risk factor for HIV, HCV and HBV transmission.
These authors acknowledged that the success in harm reduction techniques in the community might
be compromised by situations inside prison. An outcome of their study was the provision of a medical
kit containing health information leaflets and a bleach type disinfectant to IDUs in prison. The authors
claimed this was unlikely to benefit the IDUs, as time would not be available to them to adequately
clean their equipment. Facilities for cleaning equipment are not a sufficient substitute for replacing
equipment.
In Germany in 1996, two prisons, Lingen, a men’s prison with 230 inmates and Vechta, a women’s 
prison with 170 inmates introduced NEPs as a pilot project (Jacob & Stover, 2000). In Vechta, inmates
accessed needles via one of five dispensing machines. In contrast, staff handed out sterile syringes to
inmates in Lingen. In both prisons, the number of used needles returned was high although there was
no strict one-for-one policy in operation. 
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The acceptance of the NEP in the women’s prison was much greater than in the men’s prison. Jacob 
& Stover (2000) cited various reasons for this including frequent use of the needle dispensing machine
and participants positive responses to the project. As a result of the personal contact involved in the
manual distribution of sterile equipment, prisoners in Lingen were more reluctant to engage in the
uptake of sterile equipment. The different mode of distribution may have been an important factor.
Acceptance of the project among prison staff in both prisons was high. The supply of sterile needles
and syringes became part of daily routine. Among other benefits, the projects demonstrated an
increase in the use of sterile needles along with an improvement in inmates’ health status. 
Prior to the commencement of the project, a total of 54 inmates had shared needles. After the
implementation of the project, four male prisoners reported using a non-sterile needle for their last
injection (Jacob & Stover, 2000). Importantly, no increase in drug consumption was observed. The
authors concluded that needle sharing is a spontaneous response to the lack of sterile injecting
equipment. This pilot project highlights the positive benefits of introducing a harm reduction
programme within the prison system. 
Scottish Prisons
In a cross-sectional study, Bird, Gore, Hutchinson et al. (1997) aimed to determine the frequency of
injecting inside prison and the use of sterile clean needles in the previous four weeks. Two prisons, 
one in Glasgow and one in Aberdeen were involved in the study. A total of 41% and 37% of inmates in
Glasgow and Aberdeen respectively had a history of IDU. Results indicated that 37% of IDU inmates in
Glasgow and 58% of IDU inmates in Aberdeen had injected in the previous four weeks while in prison.
Although risk factors associated with sharing equipment were not examined in this study, it was noted
that IDUs had access to sterilisation tablets in prison. It was reported that the majority of injectors used
sterilisation tablets to clean needles and syringes. Bird et al. (1997) concluded that it is paramount that
prisoners who inject drugs are enabled to do so in a safe manner. They acknowledged the need for
access to other harm reduction measures such as needle exchange while in prison. 
Swiss Prisons
In 1994, a pilot project on the prevention of drug use and transmission of HIV was established in
Hindlebank, a Swiss prison for women (Nelles, Fuhrer, Hirsbrunner & Harding, 1998). This project
consisted of lectures, socio-medical counselling, and distribution of condoms and syringes by
exchange dispensers. This project was evaluated primarily using structured personal interviews with
inmates prior to the introduction of the programme and at three-monthly intervals on three occasions
following its implementation. A total of 161 inmates took part with at least 85% engaging in one
interview. Sharing of syringes amongst inmates significantly reduced during the project. At the
beginning of the project 8 of 19 IDUs reported sharing syringes the previous month with others in
prison. On completion, only one woman reported sharing injecting equipment while in prison. 
This study suggests that the availability of clean injection equipment via automated dispensers is
necessary to reduce needle sharing in prison. As in other studies (e.g. Jacob & Stover, 2000), there 
is evidence that drug consumption did not increase during the intervention. Nelles et al. (1998)
confirmed the relationship between continuing drug use in prison and the prevalence of infectious
diseases. The authors demonstrated that syringe distribution in prison was both feasible and successful
and highlights the need for effective prevention measures within prisons (Nelles et al., 1998).
Spanish Prisons
Until the 1990s Spain had policies based on abstinence. According to Rinken and Romero-Vallecillos
(2002) they also had the higher rate of HIV infection amongst the IDUs population in Europe.
Significant reductions in HIV have been reported since the introduction of extensive harm reduction
policies between 1992 and 1994 (Hernández-Aguado et al., 1999). HIV prevalence amongst Spanish
prisoners has declined from 23% in 1996 to 17% in 2001, a reduction of 6 percent in 5 years (Hunt et 
al., 2003). Hunt et al. (2003) notes that this is more likely to be attributable to the earlier introduction 
of methadone programmes along with education, counselling and condom distribution. In effect, 
a comprehensive harm reduction programme in which NEPs in prisons are one of a number of
strategies employed.
Misuse of Drugs by the Irish Prison Population
Drug consumption in prison and its implications are a major problem within the prison system (Jacob 
& Stover, 2000). Allwright et al. (1999) found 52% of a national sample of prisoners reported a history 
of opiate use, and 43% reported a history of injecting drug use. O’ Mahony (1997) states that the
problem of drug misuse for prison systems is impeded by a lack of research, and, where research
exists, by definitional ambiguities and confusions. The research does not always distinguish between
cannabis, cocaine and opiate users. O’ Mahony (1997) compares the situation in Mountjoy with the US
Survey of State Prison Inmates and finds that the incident of opiate use in the Mountjoy sample (66%)
is three times higher than in the US State prison system (25%). However, it is important to take into
account that Mountjoy, one Irish Prison, which has a concentration of drug users, is being compared to
the entire US State prison system. Those who inject in prison also report increased rates of borrowing
needles and syringes (Stark et al., 1995). 
Irish Prisons
Both Long, Allwright, Barry et al. (2001) and Allwright, Bradley, Long et al. (2001) aimed to determine
the prevalence of antibodies to HBV core antigen, HCV core antigen and HIV in the Irish prison
population and to examine risk factors for infection. 
The survey findings of the committal study (Long et al., 2001), which examined those entering Irish
prisons, echo the general findings of Allwright et al. (2001) who used a sample of those already within
the Irish prison system (census study). In the Long et al. study (2001), all newly-detained prisoners
during a 3-week time period in 5 out of the 7 Irish prisons, completed an anonymous questionnaire
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and provided an oral fluid sample for analysis. Over half the IDUs reported sharing needles in prison
with almost a fifth reporting starting their injecting habit there. Increasing time spent in prison in the
preceding 10 years and a history of injecting drug use were significant predictors of HCV antibodies
(Long et al., 2001). IDU was the most important risk factor for HCV, with injectors who reported sharing
needles in prison being more likely to test positive (Long et al., 2001; Allwright et al., 2001). 
Being in prison is associated with a move from one route of administration to another, e.g. smoking to
injecting and it has influenced the risk behaviour of prisoners in relation to the spread of blood-borne
diseases such as hepatitis and HIV (Dillon 2001). This shift in the route of administration was attributed
to the nature of drug use in prison. Dillon (2001) reported that the supply of drugs is limited, therefore,
they are taken by the perceived most efficient route. By ‘efficient’ it was meant that the greatest
number of prisoners should be able to use, to its maximum effect, the limited quantity of heroin available. 
Although the prevalence of antibodies to HCV was 22% (6% HBV; 2% HIV), Long et al. (2001) concluded
that injecting drug use and associated infections, particularly HCV, are endemic within Irish prisons. IDU
was the most important predictor of antibodies to HBV and HCV. 
Prisoners who had previously been incarcerated were more likely to test positive for HIV, HBV and HCV
compared to prisoners serving their first sentence (Long et al., 2001). The prevalence of each of these
three infections was significantly higher in women than in men. The proportion of women prisoners
who reported injecting drugs was higher than men. Allwright et al. (2001) supported this finding and
reported that women were more likely than men to report smoking heroin in the past year. This
suggests that women drug users in prison are an ‘at risk group’ needing appropriate and necessary
harm reduction programmes. 
It must be considered that both these studies are cross-sectional in nature, thus causal conclusions
cannot be drawn. Another limitation noted by Long et al. (2001) is that there is an 80% sensitivity of 
the antibody test, the prevalence of HCV antibodies in their survey therefore, is likely to be an
underestimate. True prevalence could be as high as 90% in Irish prisons. 
Allwright et al. (2001) confirm the high rates of IDU and sharing of equipment in prison. They conclude
that policy makers must ensure that a prison sentence does not increase an individual’s health risks.
The rate of HIV among Irish prisoners is more than 10 times greater than in the general population, 
the rate of HCV in excess of 100 times (Lines, 1996). 
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Key Points
■ Research indicates a practice of injecting risk behaviour among the homeless population who 
use drugs
■ Women in prostitution are an at risk group for HIV, HBV and HCV infection from both injecting 
risk behaviours and having multiple partners
■ There is evidence that drug consumption does not rise in prisons following the introduction 
of NEPs 
■ Those who inject in prison report increased rates of borrowing needles and syringes, which is
considered to be the most important risk factor in the transmission of HIV, HCV and HBV in prison
■ Irish studies show that blood-borne infections are more common in IDUs who were previously 
in prison than those who had no time in prison 
■ Women drug users in prison are an at risk group who would benefit from appropriate and
necessary harm reduction programmes
■ HIV and HCV are significantly higher among prisoners in Ireland than in the general population
■ As imprisonment leads to high-risk drug taking practices, there is a need for extended harm
reduction measures within Irish prisons
Chapter 10
Legal Issues
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Services providing harm reduction programmes need to be mindful of national and international laws
and treaties, as the range of services that can operate in a State is controlled by national legislation.
This chapter outlines the relevant Irish law and international treaties that govern the supply,
preparation and consumption of controlled drugs. Direct reference is made to the Misuse of Drugs 
Act (1977), The Misuse of Drugs Regulations (1988), the United Nations Single Convention on Narcotic
Drugs (1961), and the International Narcotic Control Board (INCB) annual report (2002). 
Over the last 80 years, a worldwide system for control of drugs abuse has developed gradually through
the adoption of a series of international treaties. The important multilateral conventions currently in
force include the Single Convention on Narcotic Drugs, 1961, amended by the 1972 Protocol, the
Convention on Psychotropic Substances, 1971, adopted in 1988, and the United Nations Convention
against Illicit Traffic in Narcotic Drugs and Psychoactive Substances. Each successive treaty has led to
complementary regulations and advances in international law. From their outset, the basic aim of the
international drug control treaties has been to limit the use of drugs to medical and scientific purposes
only (INCB 2003). 
This report is concerned with the range of harm reduction measures aimed at minimising sharing of
equipment used to administer drugs. The drugs heroin and cocaine, as outlined above, are frequently
smoked or injected thus requiring equipment for their administration. Harm reduction measures range
from communicating with drug misusers to the provision of equipment to administer drugs, and, as
described in Chapter 5, supervised consumption rooms. The prescription and provision of heroin for
consumption is argued by some to be a harm reduction measure. However, where such prescription
and provision has taken place, (the United Kingdom, Switzerland and the Netherlands) it has clearly
been described as treatment and/or research (Ali et al., 1998, Hall, 1999, Uchtenhagen et al., 1999, 
Van Den Brink et al., 1999, Zador, 2001 & Hunt et al., 2003). The INCB (2002) annual report notes the
evaluation of the heroin maintenance programme undertaken by the Government of the Netherlands,
which highlights both the advantages and disadvantages of such programmes. The Board reiterates 
its reservations from previous years (INCB 2003, 2002, 2001, 1999), that the evidence is not convincing
even in cases where methadone treatment had persistently failed, that the medical prescription of
heroin generally leads to better results than further methadone treatment. In view of the conclusion 
of the External Panel and mindful of the responsibilities according to it in the international drug 
control treaties, the Board remains concerned over the Swiss heroin programme and policy of heroin
prescription. The Board does not encourage other governments to allow heroin to be prescribed to
opiate addicts (INCB 1999). Heroin provision is not part of the harm reduction approach in Ireland. 
Drug Schedules
The list of Narcotic drugs under international control (Yellow list 2002) includes cocaine (methyl ester 
of benzoylecgonine), heroin (diacetylmorphine) and methadone (6-diemethylamino-4, 4-diphenyl-3-
heptanone). In Irish law, cocaine, diamorphine (pharmaceutical heroin) and methadone, are listed as
Schedule II drugs. The Misuse of Drugs Act 1977 and the Misuse of Drugs Regulations 1988 provide 
for a wide range of controls over drugs that have the potential to be misused. They include controls
relating to importation, exportation, cultivation, licensing, administration, supply, record keeping,
prescription writing, destruction and safe custody (Misuse of Drugs Act 1997, Misuse of Drugs
Regulations 1988, Moran et al., 2001). 
Production and Administration of Controlled Drugs
Part II of the Misuse of Drugs Regulations (1988) states that a person shall not produce a controlled
drug, supply or offer to supply a controlled drug, or import or export a controlled drug. The
regulations make provision for the Minister to grant a licence to supply, offer to supply, import, 
export or have in his possession any controlled drug to which the licence relates. 
Administration of Schedule II drugs is regulated under Section 6 of the Misuse of Drugs Regulations
(1998), and permits registered medical practitioners or registered dentists or any person in accordance
with their directions to administer Schedule II drugs to another person. 
Practitioners and pharmacists may, when acting in their professional capacity, supply Schedule II drugs
to any person who may lawfully have the drug in his possession. 
Possession of Controlled Drugs
Part III of the regulations allows for possession of controlled drugs for administration for medical,
dental or veterinary proposes, in accordance with the direction of a practitioner. Other general
authorities are also allowed to keep controlled drugs in their possession when it relates to conducting
their work. These authorities include, a member of the Garda Síochána, a Customs and Excise Officer, a
person authorised in writing by the Minister acting in the course of his duties (such as a postal worker),
a person engaged in work in a laboratory, a person engaged in the business of carrier, when acting
bona fide in the course of that business, or a person engaged in conveying the drug to a person
authorised by the regulations to have it in his possession. 
Regulations in Relation to Preparing and Consuming Controlled Drugs
Section 16 of the Misuse of Drugs Act (1997) prohibits people from smoking or otherwise using
prepared opium. It also prohibits the frequenting of a place used for the purpose of smoking or
otherwise using prepared opium. Subsection 16.c. (i) prohibits a person from having in their possession
any pipes or other utensils made or adapted for use with the smoking of opium (Misuse of Drugs 
Act 1997). The Misuse of Drugs Act (1997) also set out in law a prohibition on the occupiers and or
managers of any land, vehicle or vessel from permitting or tolerating the preparation and/or smoking
of opium, cannabis or a controlled drug. These restrictions in Irish law would clearly prevent any
organisation from opening or operating a drug consumption room where drug users could prepare
and consume their illicit drugs. 
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Establishing drug-injecting rooms, where drug abusers can inject drugs that they have acquired from
illicit sources, is contrary to international drug control treaties (INCB 2002). The INCB (2002) criticised
the opening of a drug consumption room in Switzerland in 2002 on the basis that the facility was not
opened with the claim that it was necessary to reduce risks to the general public and to illicit drug
users. Drug injecting rooms (or any other similar outlets established in some developing countries)
might even facilitate drug abuse, are contrary to international drug control treaties and interfere with
obligations of law enforcement authorities (INCB 2002). Similarly the Board maintains its opposition,
expressed in its report of 2001 on the establishment in Australia of a drug injecting room, and regrets
that the project has been extended (INCB 2002). 
Key Points
■ International treaties exist to limit the use of drugs to medical and scientific purposes only
■ National legislation outlines a number of controls on the prescription, possession and consumption
of controlled drugs
■ There is scope in Irish law for the prescription of Schedule II drugs by medical practitioners and
other defined agents
■ A licence is required to import, export or manufacture a Schedule II drug 
■ The INCB has criticised drug consumption rooms in both Australia and Switzerland
■ Under current Irish law it is not permissible to legally operate a drug-consumption facility
Chapter 11
Conclusions A R
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Harm reduction strategies operating nationally and internationally have been reviewed in this report,
with an emphasis on the sharing of drug-taking paraphernalia, the transmission of blood-borne disease
and the needs of particularly marginalised groups. Given the range and extent of literature reviewed in
this report, and the contribution made by the exploratory empirical research, it is clear that this critical
analysis of harm reduction approaches has the potential to inform practice in Irish drugs’ services. 
Harm reduction efforts focus on minimising the personal and social harm associated with drug use and
the spread of blood-borne disease. International trends in harm reduction have become established
during the past three decades. These trends are reflected in Irish Government policy since 1992 and
clearly inform the National Drug Strategy (2001-2008). 
Harm reduction programmes operate in a range of settings in Ireland, including fixed sites, mobile
units and outreach settings. Harm reduction programmes normally draw on a knowledge and means
model of behaviour change, including ongoing treatment for drug misusers.
The international research reviewed indicates that treatment and prevention interventions are more
successful in containing the spread of HIV than containing HCV, and that the duration of drug misuse 
is generally associated with acquiring HCV among IDUs. Where comprehensive harm reduction
programmes exist, lower rates of infection are reported suggesting that harm reduction has a role 
in managing and limiting some of the negative outcomes associated with sustained drug misuse. 
High levels of unsafe injecting practice have been found among young Irish IDUs, which helps to
explain the early acquisition of HCV by IDUs in Dublin. Understanding this pattern requires an analysis
of trends elsewhere in borrowing equipment, particularly in young populations, which suggests that
messages about managing high-risk behaviour are not being transmitted effectively to young IDUs. 
A number of factors may be influencing this, including the accessibility of services (e.g. location,
opening hours), issues around consent, the strategies used to convey harm reduction messages, 
and the preparation of staff. 
The research indicates that ease of access to services is a factor in the transmission of blood-borne
infections. IDUs frequently report sharing needles and syringes because of the perceived difficulty in
acquiring clean equipment. It is also noteworthy that substantial variation exists in the local availability
and accessibility of services in Ireland. 
All of the routes of drug administration that require the use of equipment increase the risk of the
transmission of HIV and HCV, particularly when equipment is shared. NEPs have been successful in
reducing the risk of sharing needles and syringes, but have not made a significant impact on the
sharing of other injecting paraphernalia. It is evident from the literature reviewed that sharing drug-
taking paraphernalia is a common practice. This poses a major risk to the health and well-being of 
the user and has implications for the spread of diseases including HIV, HBV and HCV. Contaminated
spoons, water or solvents, filters, and pipes may spread bacterial and viral infections. Spoons are the
most frequently shared piece of injecting paraphernalia. The exploratory research indicates that drug
services differ in the range of paraphernalia that is offered to IDUs. 
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Another phenomenon identified in the literature that influences risk-taking behaviour in relation to
injecting drugs is the change in trends of drug use that can occur relatively quickly. These changes
require users to administer their drugs differently. 
Public concerns about harm reduction as an approach to the management of problem drug use
appears to centre on the legalisation of illicit substances, criminal activity associated with illicit drug
use and risks to public health from contact with used drug-taking paraphernalia. These concerns 
have been influential in the establishment of harm reduction programmes both nationally and
internationally. Despite fears to the contrary, there is evidence that NEPs are effective in preventing 
HIV infection without being associated with a rise in drug use. 
The factors most frequently associated with the sharing of equipment include youth, a shorter injecting
history and being involved in a sexual relationship with other IDUs. The research indicates that young
injectors are not receiving the harm reduction message of safe injecting practices. Unprotected sexual
activity by those who are sharing paraphernalia needs to be addressed within a harm reduction
programme. 
Intravenous drug use often occurs in locations with limited accessibility to NEPs. Internationally,
supervised consumption rooms have been introduced in a number of sites with a purpose of
responding to high levels of overdose and to reduce the nuisance from street drug use. The goals
associated with the introduction of supervised consumption rooms include the reduction of the
incidence of blood-borne disease transmission, improvements in the general health of IDUs and
increased contact with appropriate primary health care and social services. Supervised consumption
rooms are a way of increasing contact with the most marginalized drug users. However, the research to
date on the effectiveness of drug consumption rooms is inconclusive as to their effectiveness as a harm
reduction strategy. It is noteworthy that the introduction of supervised consumption rooms in Ireland
would require changes in legislation. 
Heroin provision has also been trialed internationally and is considered part of the harm reduction
strategy in some countries. There is a limited amount of research to support the introduction of this
strategy. The limited trials that have been conducted to date do not show that heroin provision alone
provides significant harm reduction outcomes for drug misusers. 
Problem drug users are a marginalised group in society. Within this group there are subsets of users
with particular needs, including people who are homeless, young people, women, sex workers and
prisoners. Research with people who are homeless indicates a relatively high rate of injecting risk
behaviour amongst those who use drugs. People in prostitution are at risk both from injecting risk
behaviour and having multiple partners. All of these groups have particular needs that influence the
level of risk they encounter, and the evidence supports developing a rationale for providing tailored
services to each group. 
Needle and syringe sharing in prison has proved to be the most important risk factor for contracting
HIV, HCV and HBV. HIV and HCV are significantly higher among prisoners in Ireland than in the general
population. Those who inject in prison also report high rates of borrowing. Irish studies show that
blood-borne infections were more common among drug injectors who had previously been in prison
than injectors who had not. There are no harm reduction services in prisons in Ireland although
treatment through the provision of methadone is now available in many prisons.
Minimising the sharing of equipment used to administer drugs is clearly established in national and
international research as reducing risks to drug users. There is no evidence to suggest that introduction
of harm reduction approaches increases the use of illicit drugs. The evidence suggests that harm
reduction programmes are effective in reducing costs both fiscal and social in countries where harm
reduction programmes are established. 
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Questionnaire for Irish Service Providers
Good Morning/Evening
I am ________________________________________________
As part of a research team in Dublin City University we are currently conducting a review of harm
reduction aimed at minimising sharing of equipment used to administer drugs. 
The National Advisory Committee on Drugs (NACD) funds this project.
To date we have conducted a literature review, which has highlighted important issues in harm
reduction. 
In order to complete this project and give it an Irish context we are now seeking information from
service providers nationally about any harm reduction services they operate. 
I would be grateful if you could answer some questions about harm reduction in your service. 
(Or put me in contact with someone in the service who could answer the questions.)
To answer all the questions takes between 20 and 30 minutes. 
Is this a convenient time for you? If not, could you suggest a suitable time that I could ring back. 
Ask questions.
Thank you for you help and support.
Goodbye. 
A harm reduction approach to drug addiction focuses on reducing the harm that substance misusers
do to themselves and to their families. A harm reduction approach aims to reduce the transmission of
HIV, hepatitis and other infectious diseases and to maximise service users’ health. 
1. What is your role in the service?
2. What addictions does your service treat?
3. Does your service offer a harm reduction programme?
Yes No
4. What is the purpose of this harm reduction programme?
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5. What harm reduction programme does your service offer?
■ Needle exchange
■ Methadone maintenance (high          medium           low         threshold)
■ Replacement drugs please specify __________________________________________
■ Needles
■ Syringes
■ One-for-one needle exchange
■ Payment for sterile needles/syringes
■ Alcohol wipes
■ Sterile water
■ Citric acid
■ Filters
■ Spoons
■ Pipes
■ Does it promote safety in sharing other injection paraphernalia?
■ Is it monitored?
■ Does it have specific targets (i.e. particular groups of drug users)?
■ Are there specific areas of harm reduction addressed, such as
■ HIV
■ Hep C 
■ Hep B 
■ Other please specify _______________________________________________________
■ Does harm reduction include specific issues such as
■ Choosing, rotating and caring for injection sites
■ Demonstration of safe injection sites
■ Discussion on specific injecting techniques (booting, frontloading)
■ Is there a formal record made to confirm what harm reduction 
advice and skills training the user has received
■ Please describe any other harm reduction strategies that are employed in your service
6. Can you please describe this harm reduction service in terms of
■ Opening hours _______________________________________________________________________
■ Who can access this service 
i. Referrals only 
ii. Walk in off street
iii. Registered user 
iv. Other please specify _______________________________________________
■ How and where is this service advertised? _______________________________________________
■ Location (outreach)? __________________________________________________________________
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7. Who are the various staff that work on the harm reduction programme?
8. What training have you received in harm reduction?
■ When did this training occur?
■ Less than 6 months ago
■ Between 6-12 months ago
■ Between 1-3 years ago
■ Between 3-5 years ago
■ Greater than 5 years ago please specify _____________________________________
9. What link {formal (F) or informal (I)} do you have with other agencies?
GPs F I
Mental health agencies F I
Hospitals F I
Pharmacies F I
Prisons F I
Probation officers F I
Voluntary organisations F I
Drug courts F I
Self-help groups F I 
Other F I __________________________
10. In your opinion, how do your operational policies/guidelines translate into practice?
11. What challenges if any does your service face in implementing service policy/guidelines?
12. In what ways (if any) does service provision depart from service policy/guidelines?
13. How can this service be developed further?
14. Are you aware if there is specific funding for the harm reduction programme in your service? 
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15. Are there any legal issues surrounding the implementation and/or running of this harm reduction
programme that may impact on its effectiveness?
16. Any other comments?
Appendix B
NACD Treatment Subcommittee Membership
Dr Eamon Keenan, Chair, Consultant Psychiatrist
Dr Joe Barry, ERHA, Public Health Specialist
Mr Liam O’Brien, Community Representative
Mr Willie Collins, Regional Health Boards’ Representative
Dr Ide Delargy, ICGP 
Ms Frances Nangle Connor, Irish Prisons Authority
Dr Hamish Sinclair, Drug Misuse Research Division, Health Research Board
Mr David Moloney, Department of Health and Children
Mr Tony Geoghegan, Irish Association of Addiction and Alcohol Counsellors
Dr Derval Howley, National Drug Strategy Team
Mr John Kelly, Department of Community Rural & Gaeltacht Affairs
Mr David Keenan, Voluntary Drug Treatment Network (Resigned Nov 2003)
Ms Mairéad Lyons, Director, NACD
Ms Aileen O’Gorman, Research Officer, NACD
Mr Muiris O’Conchuir and Mr Alan Gaffney, former and current Secretary to the Committee respectively.
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Appendix C
Harm Reduction Research Advisory Group
Dr Joe Barry
Dr Derval Howley
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Gerard Moore 
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